Opioid epidemic in the United States
Parts of this article (those related to Charts) need to be updated.(November 2020)
The opioid epidemic (also known as the opioid crisis) refers to the extensive overuse of opioid medications, both from medical prescriptions and from illegal sources. The epidemic began in the United States in the late 1990s, when opioids were increasingly prescribed for pain management and resulted in a rise in overall opioid use throughout subsequent years.
From 1999 to 2017, more than 399,000 people died from drug overdoses that involved prescription and illicit opioids. In 2017 alone, there were 70,237 recorded drug overdose deaths, and of those deaths, 47,600 involved an opioid. A report from December 2017 estimated 130 people every day in the United States die from an opioid-related drug overdose. Use of opioids constitutes a public health emergency. The great majority of Americans who use prescription opioids do not believe that they are misusing them.
Those addicted to opioids, both legal and illegal, are increasingly young, white, and female, with 1.2 million women addicted compared to 0.9 million men in 2015. The problem is worse in rural areas. Teen use of opioids has been noticeably increasing since 2006, using prescription drugs more than any illicit drug except cannabis; more than cocaine, heroin, and methamphetamine combined.
In 2011, the Obama administration began to deal with the crisis, and in 2016, President Barack Obama authorized millions of dollars in funding for opioid research and treatment, followed by Centers for Disease Control director, Dr. Thomas Frieden, stating that "America is awash in opioids; urgent action is critical." Soon after, many state governors declared a "state of emergency" to combat the opioid epidemic in their own states, and undertook major efforts to stop it. In July 2017, opioid addiction was cited as the "Food and Drug Administration's biggest crisis", followed by President Donald Trump declaring the opioid crisis a "national emergency." In September 2019, he ordered U.S. mail carriers to block shipments of fentanyl coming from other countries.
Opioids are a diverse class of moderately strong, addictive, and inexpensive drugs, which include opiates (i.e., morphine and codeine), oxycodone (OxyContin, Percocet), hydrocodone (Vicodin, Norco), and fentanyl. Traditionally, opioids have been prescribed for pain management, as they are effective for treating acute pain but are less effective for treating chronic pain. Clinical guidelines advise that opioids should only be used for chronic pain if safer alternatives are not feasible, as their risks often outweigh their benefits.
The potency and availability of opioids have made them popular as both medical treatments and recreational drugs. In 2018, the U.S. opioid prescription rate was 51.4 prescriptions per 100 people, which is equivalent to more than 168 million total opioid prescriptions. However, these substances also have high risks of addiction and overdose, and long-term use can cause tolerance and physical dependence. When people continue to use opioid medications beyond what a doctor prescribes, whether to minimize pain or induce euphoric feelings, it can mark the beginning stages of an opiate addiction. Also in 2018, after being prescribed an opioid medication, about 10.3 million people ended up misusing it and 47,600 people died from an overdose.
The Centers for Disease Control and Prevention describe the U.S. opioid epidemic to have arrived in three waves.
The first wave, which marked the start of the epidemic, began in the 1990s due to the push towards using opioid medications for chronic pain management and the increased promotion by pharmaceutical companies for medical professionals to use their opioid medications. During this time, around 100 million people in the United States were estimated to be affected by chronic pain; however, opioids were only reserved for acute pain experienced secondary to cancer or terminal illnesses. Physicians avoided prescribing opioids for other medical conditions because of the lack of evidence supporting their use, the concern of opioids having addictive properties, and the fear of being investigated or disciplined for liberal opioid practices. However, in 1980, a letter to the editor featured in the New England Journal of Medicine (NEJM) challenged these notions and advocated for more liberal use of opioids in pain management, which was eventually supported by the World Health Organization. In addition to this, medical organizations began to push for more attentive physician response to pain, referring to pain as the "fifth vital sign". This was coupled with the promotion of opioids by pharmaceutical companies who insisted that patients could not become addicted. Opioids became an acceptable form of treatment for a wide variety of conditions, and this led to a consistent increase in opioid prescriptions. From 1990 to 1999, the total number of opioid prescriptions grew from 76 million to approximately 116 million, which led to them becoming the most prescribed class of medications in the United States.
Mirroring the positive trend in the volume of opioid pain relievers prescribed is an increase in the admissions for substance use disorder treatments and increase in opioid-related deaths. This illustrates how legitimate clinical prescriptions of pain relievers are being diverted through an illegitimate market, leading to misuse, addiction and death. With the increase in volume, the potency of opioids also increased. By 2002, one in six drug users were being prescribed drugs more powerful than morphine; by 2012, the ratio had doubled to one-in-three. The most commonly prescribed opioids have been oxycodone and hydrocodone.
The second wave of the opioid epidemic started around 2010 and is characterized by the rise in heroin use and overdose deaths. Between 2005 and 2012, the number of people who used heroin almost doubled from 380,000 to 670,000, and in 2010, there were a total of 2,789 fatal heroin overdoses, an almost 50% increase from the years prior. This spike is a reflection of the increase in heroin supplies in the United States and the decrease in prices, which encouraged a large proportion of individuals with an established dependency and tolerance on opioids to transition towards a more concentrated and cheaper alternative. During this same time period, there was also a reformulation of OxyContin that made it more difficult to be able to crush it and use it; however, the effect of this formulation on the rise in heroin use is still unclear.
The third and most recent wave of the opioid epidemic began in 2013 and is ongoing. This wave coincides with the steep rise in overdose deaths that involved synthetic opioids, particularly illegally produced fentanyl.
The epidemic has been described as a "uniquely American problem".[verification needed] The structure of the U.S. healthcare system, in which people not qualifying for government programs are required to obtain private insurance, favors prescribing drugs over more expensive therapies. According to Professor Judith Feinberg, "Most insurance, especially for poor people, won't pay for anything but a pill." Prescription rates for opioids in the United States are 40 percent higher than the rate in other developed countries such as Germany or Canada. While the rates of opioid prescriptions increased between 2001 and 2010, the prescription of non-opioid pain relievers (aspirin, ibuprofen, etc.) decreased from 38% to 29% of ambulatory visits in the same time period, and there has been no change in the amount of pain reported in the United States. This has led to differing medical opinions, with some noting that there is little evidence that opioids are effective for chronic pain not caused by cancer.
The annual opioid prescribing rates has been slowly decreasing since 2012, but the number is still high. There were about 58 opioid prescriptions per 100 Americans in 2017. Characteristics of jurisdictions with a greater number of opioid prescriptions per resident include: small cities or large towns; cities with more dentists and primary care doctors per capita; cities with a higher percentage of white residents; cities with a higher uninsured/unemployment rate; and cities with more residents who have diabetes, arthritis, or a disability.
Several studies have been conducted to find out how opioids were primarily acquired, with varying findings. A 2013 national survey indicated that 74% of people who recreationally use opioids acquired their opioids directly from a single doctor, or a friend or relative, who in turn received their opioids from a clinician. Among pharmacies, the most prolific distributor was Walgreens, which bought 13 billion oxycodone and hydrocodone pills from 2006 through 2012 (about twenty percent of all such pills in US pharmacies). Though aggressive opioid prescription practices played the biggest role in creating the epidemic, the popularity of illegal substances such as potent heroin and illicit fentanyl have become an increasingly large factor. It has been suggested that decreased supply of prescription opioids caused by opioid prescribing reforms turned people who were already addicted to opioids towards illegal substances.
In 2015, approximately 50% of drug overdoses were not the result of an opioid product from a prescription, though most recreational users' first exposure had still been by lawful prescription. By 2018, another study suggested that 75% of people who use opioids recreationally started their opioid use by taking drugs which had been obtained in a way other than by legitimate prescription.
The top line represents the yearly number of benzodiazepine deaths that involved opioids in the United States. The bottom line represents benzodiazepine deaths that did not involve opioids.
Mike Strobe, AP medical writer
|Treating America's Opioid Addiction Part 1: The Narcotic Farm and the Promise of Salvation|
|Part 2: Synanon and the Tunnel Back to the Human Race|
|Part 3: Searching for Meaning in Kensington, Science History Institute|
Opiates such as morphine have been used for pain relief in the United States since the 1800s, and were used during the American Civil War. Opiates soon became known as a wonder drug and were prescribed for a wide array of ailments, even for relatively minor treatments such as cough relief. Bayer began marketing heroin commercially in 1898. Beginning around 1920, however, the addictiveness was recognized, and doctors became reluctant to prescribe opiates. Heroin was made an illegal drug with the Anti-Heroin Act of 1924, in which the US Congress banned the sale, importation, or manufacture of heroin.
In the 1950s, heroin addiction was known among jazz musicians, but still fairly uncommon among average Americans, many of whom saw it as a frightening condition. The fear extended into the 1960s and 1970s, although it became common to hear or read about drugs such as cannabis and psychedelics, which were widely used at rock concerts like Woodstock.
Heroin addiction began to make the news around 1970 when rock star Janis Joplin died from an overdose. During and after the Vietnam War, addicted soldiers returned from Vietnam, where heroin was easily bought. Heroin addiction grew within low-income housing projects during the same time period. In 1971, congressmen released an explosive report on the growing heroin epidemic among US servicemen in Vietnam, finding that ten to fifteen percent were addicted to heroin. "The Nixon White House panicked," wrote political editor Christopher Caldwell, and declared drug abuse "public enemy number one". By 1973, there were 1.5 overdose deaths per 100,000 people.
Modern prescription opiates such as Vicodin and Percocet entered the market in the 1970s, but acceptance took several years and doctors were apprehensive about prescribing them. Until the 1980s, physicians had been taught to avoid prescribing opioids because of their addictive nature. A brief letter published in the New England Journal of Medicine (NEJM) in January 1980, titled "Addiction Rare in Patients Treated with Narcotics", generated much attention and changed this thinking. A group of researchers in Canada claim that the letter may have originated and contributed to the opioid crisis. The NEJM published its rebuttal to the 1980 letter in June 2017, pointing out among other things that the conclusions were based on hospitalized patients only, and not on patients taking the drugs after they were sent home. The original author, Dr. Hershel Jick, has said that he never intended for the article to justify widespread opioid use.
In the mid-to-late 1980s, the crack epidemic followed widespread cocaine use in American cities. The death rate was worse, reaching almost 2 per 100,000. In 1982, Vice President George H. W. Bush and his aides began pushing for the involvement of the CIA and the US military in drug interdiction efforts, the so-called War on Drugs. The initial promotion and marketing of OxyContin was an organized effort throughout 1996–2001, to dismiss the risk of opioid addiction.
Purdue Pharma hosted over forty promotional conferences at three select locations in the southwest and southeast of the United States. Coupling a convincing "Partners Against Pain" campaign with an incentivized bonus system, Purdue trained its salesforce to convey the message that the risk of addiction was under one percent, ultimately influencing the prescribing habits of the medical professionals that attended these conferences. Consulting firm McKinsey & Company reached a nearly $600 million settlement with 49 of 50 U.S. states in 2021 over the firm's role in driving opioid sales for Purdue Pharma and other pharmaceutical companies. In 2016, the opioid epidemic was killing on average 10.3 people per 100,000, with the highest rates including over 30 per 100,000 in New Hampshire and over 40 per 100,000 in West Virginia.
According to the Substance Abuse and Mental Health Services Administration's National Survey on Drug Use and Health, in 2016 more than 11 million Americans misused prescription opioids, nearly 1 million used heroin, and 2.1 million had an addiction to prescription opioids or heroin.
While rates of overdose of legal prescription opiates have leveled off in the past decade, overdoses of illicit opiates have surged since 2010, nearly tripling.
In a 2015 report, the US Drug Enforcement Administration stated that "overdose deaths, particularly from prescription drugs and heroin, have reached epidemic levels.":iii Nearly half of all opioid overdose deaths in 2016 involved prescription opioids. From 1999 to 2008, overdose death rates, sales, and substance use disorder treatment admissions related to opioid pain relievers all increased substantially. By 2015, there were more than 50,000 annual deaths from drug overdose, causing more deaths than either car accidents or guns.
In 2016, around 64,000 Americans died from overdoses, 21 percent more than the approximately 53,000 in 2015. By comparison, the figure was 16,000 in 2010, and 4,000 in 1999. While death rates varied by state, in 2017 public health experts estimated that nationwide over 500,000 people could die from the epidemic over the next 10 years. In Canada, half of the overdoses were accidental, while a third were intentional. The remainder were unknown. Many of the deaths are from an extremely potent opioid, fentanyl, which is trafficked from Mexico. The epidemic cost the United States an estimated $504 billion in 2015.
In 2017, around 70,200 Americans died from drug overdose. 28,466 deaths were associated with synthetic opioids such as fentanyl and fentanyl analogs, 15,482 were associated with heroin use, 17,029 with prescription opioids (including methadone), 13,942 with cocaine use, and 10,333 with psychostimulants (including methamphetamine).
Between 2017 and 2019, rappers Lil Peep, Mac Miller, and Juice Wrld died of drug overdoses related to opioids. William D. Bodner of the Drug Enforcement Administration's Los Angeles field division and special agent in charge of the investigation into Miller's death said in a statement, “The tragic death of Mac Miller is a high-profile example of the tragedy that is occurring on the streets of America every day.”
Between 4–6% of people who misuse prescription opioids turn to heroin, and 80% of heroin addicts began abusing prescription opioids. Many people addicted to opioids switch from taking prescription opioids to heroin because heroin is less expensive and more easily acquired on the black market.
Heroin use has been increasing over the years. An estimated 374,000 Americans used heroin in 2002–2005, and this estimate grew to nearly double where 607,000 of Americans had used heroin in 2009–2011. In 2014, it was estimated that more than half a million Americans had an addiction to heroin.
Oxycodone is the most widely used recreational opioid in the United States. The US Department of Health and Human Services estimates that about 11 million people in the US consume oxycodone in a non-medical way annually.
Oxycodone was first made available in the United States in 1939. In the 1970s, the FDA classified oxycodone as a Schedule II drug, indicating a high potential for non-medical use and addiction. In 1996, Purdue Pharma introduced OxyContin, a controlled release formulation of oxycodone. However, drug users quickly learned how to simply crush the controlled release tablet to swallow, inhale, or inject the high-strength opioid for a powerful morphine-like high. In fact, Purdue's private testing conducted in 1995 determined that 68% of the oxycodone could be extracted from an OxyContin tablet when crushed.
In 2007, Purdue paid $600 million in fines after being prosecuted for making false claims about the risk of opioid use disorder associated with oxycodone. In 2010, Purdue Pharma reformulated OxyContin, using a polymer to make the pills extremely difficult to crush or dissolve in water to reduce non-medical use of OxyContin. The FDA approved relabeling the reformulated version as abuse-resistant. OxyContin use following the 2010 reformulation declined slightly while no changes were observed in the use of other opioids.
In June 2017, the FDA asked the manufacturer to remove its long-acting form of oxymorphone (Opana ER) from the US market, because the drug's benefits may no longer outweigh its risks, this being the first time the agency has asked to remove a currently marketed opioid pain medication from sale due to public health consequences of non-medical use.
Hydrocodone is second among the list of top prescribed opioid painkillers, but it is also high on the list of most frequently used for recreational use. In 2011, the non-medical use of hydrocodone was responsible for more than 97,000 visits to the emergency room. In 2012, the Food and Drug Administration (FDA) rescheduled it from a Schedule III drug to a Schedule II drug, recognizing its high potential for non-medical use and addiction.
Hydrocodone can be prescribed under a different brand name. These brand names include Norco, Lortab, and Vicodin. Hydrocodone can also exist in other formulations where it is combined with another non-opioid pain reliever such as acetaminophen, or even a cough suppressant.
When opioids like hydrocodone are taken as prescribed, for the indication prescribed, and for a short period of time, then the risk of non-medical use and addiction is small. Problems have surfaced over the last decade however, due to its wide overuse and misuse in the setting of chronic pain.
The elderly are at an increased risk for opioid related overdose because several different classes of medications can interact with opioids and older patients are often taking multiple prescribed medications at a single time. One class of drug that is commonly prescribed in this patient population is benzodiazepines. Benzodiazepines by themselves put older people at risk for falls and fractures due to associated side effects related to dizziness and sedation. Opioids by themselves put older people at risk of respiratory depression and impaired ability to operate vehicles and other machinery. Combining these two drugs together not only increases a person's risk of the aforementioned adverse effects, but it can increase a person's risk of overdose and death.
Statistics show that hydrocodone ranks in at number 4 on the list of the most common drugs used recreationally in the United States and that more than 40% of drug-related emergencies occur due to opioid use disorder. Twenty percent of people who use opioids recreationally, another statistic reports, were prescribed the medication they used.
Hydrocodone was declared the most widely prescribed opioid between 2007 and 2016, and in 2015 the International Narcotics Control Board reported that greater than 98% of the hydrocodone consumed in the entire world was consumed by Americans.
Codeine is a prescription opiate used to treat mild to moderate pain. It is available as a tablet and cough syrup. Approximately 33 million people use codeine each year. A 2013 study on the concoction of codeine with alcohol or soda, also known as "purple drank," discovered that codeine is most widely used in a recreational way by men, Native Americans and Hispanics, urban students, and LGBT persons. The study also noted that all people who used "purple drank" reported using alcohol within the past month, and roughly 10 percent of cannabis users reported abusing "purple drank".
Adolescent use of prescription codeine for recreational use raises concerns. In 2008, the SAMHSA reported 3 million young adults, ranging from ages 12 to 25, had used codeine-based cough syrup to get high. In 2014, 467,000 American adolescents used these opiates for non-medical purposes, and 168,000 of these were considered to have an addiction. Due to its high rates of non-medical use, the Drug Enforcement Administration (DEA) reclassified codeine as Schedule III for increased meticulous monitoring.
Fentanyl, a synthetic opioid painkiller, is 50 to 100 times more potent than morphine and 30 to 50 times more potent than heroin, with only 2 mg becoming a lethal dose. It is pure white, odorless and flavorless, with a potency strong enough that police and first responders helping overdose victims have themselves overdosed by simply touching or inhaling a small amount. As a result, the Drug Enforcement Administration has recommended that officers not field test drugs if fentanyl is suspected, but instead collect and send samples to a laboratory for analysis. "Exposure via inhalation or skin absorption can be deadly," they state.
Over a two-year period, close to $800 million worth of fentanyl pills were illegally sold online to the US by Chinese distributors. The drug is usually manufactured in China, then shipped to Mexico where it is processed and packaged, which is then smuggled into the US by drug cartels. A large amount is also purchased online and shipped through the US Postal Service. It can also be purchased directly from China, which has become a major manufacturer of various synthetic drugs illegal in the US. AP reporters found multiple sellers in China willing to ship carfentanyl, an elephant tranquilizer that is so potent it has been considered a chemical weapon. The sellers also offered advice on how to evade screening by US authorities. According to Assistant US Attorney, Matt Cronin:
It is a fact that the People's Republic of China is the source for the vast majority of synthetic opioids that are flooding the streets of the United States and Western democracies. It is a fact that these synthetic opioids are responsible for the overwhelming increase in overdose deaths in the United States. It is a fact that if the People's Republic of China wanted to shut down the synthetic opioids industry, they could do so in a day.
Deaths from fentanyl in 2016 increased by 540 percent across the United States since 2015. This accounts for almost "all the increase in drug overdose deaths from 2015 to 2016", according to a study published in the Journal of the American Medical Association.
Fentanyl-laced heroin has become a big problem for major cities, including Philadelphia, Detroit and Chicago. Its use has caused a spike in deaths among users of heroin and prescription painkillers, while becoming easier to obtain and conceal. Some arrested or hospitalized users are surprised to find that what they thought was heroin was actually fentanyl. According to former CDC director Tom Frieden:
As overdose deaths involving heroin more than quadrupled since 2010, what was a slow stream of illicit fentanyl, a synthetic opioid 50 to 100 times stronger than morphine, is now a flood, with the amount of the powerful drug seized by law enforcement increasing dramatically. America is awash in opioids; urgent action is critical.
According to the Centers for Disease Control and Prevention (CDC), death rates from synthetic opioids, including fentanyl, increased over 72% from 2014 to 2015. In addition, the CDC reports that the total deaths from opioid overdoses may be under-counted, since they do not include deaths that are associated with synthetic opioids which are used as pain relievers. The CDC presumes that a large proportion of the increase in deaths is due to illegally-made fentanyl; as the statistics on overdose deaths (as of 2015) do not distinguish pharmaceutical fentanyl from illegally-made fentanyl, the actual death rate could, therefore, be much higher than reported.
Those taking fentanyl-laced heroin are more likely to overdose because they do not know they also are ingesting the more powerful drug. The most high-profile death involving an accidental overdose of fentanyl was singer Prince.
Fentanyl has surpassed heroin as a killer in several locales: in all of 2014 the CDC identified 998 fatal fentanyl overdoses in Ohio, which is the same number of deaths recorded in just the first five months of 2015. The US Attorney for the Northern District of Ohio stated:
One of the truly terrifying things is the pills are pressed and dyed to look like oxycodone. If you are using oxycodone and take fentanyl not knowing it is fentanyl, that is an overdose waiting to happen. Each of those pills is a potential overdose death.
In 2016, the medical news site STAT reported that while Mexican cartels are the main source of heroin smuggled into the US, Chinese suppliers provide both raw fentanyl and the machinery necessary for its production. In Southern California, a home-operated drug lab with six pill presses was uncovered by federal agents; each machine was capable of producing thousands of pills an hour.
Overdoses involving fentanyl have greatly contributed to the havoc caused by the opioid epidemic. In New Hampshire, two thirds of the fatal drug overdoses involved fentanyl, and most do not know that they are taking fentanyl. In 2017, a cluster of fentanyl overdoses in Florida was found to be caused by street sales of fentanyl pills sold as Xanax. According to the DEA, one kilogram (2.2 lb) of fentanyl can be bought in China for $3,000 to $5,000, and then smuggled into the United States by mail or Mexican drug cartels to generate over $1.5 million in revenue. The profitability of this drug has led dealers to adulterate other drugs with fentanyl without the knowledge of the drug user.
One study found that, although relatively uncommon, "the presence of fentanyl in the stimulant supply increased significantly between 2011 and 2016, with the greatest increases occurring between 2015-2016; the presence of these products was concentrated in the U.S. Northeast."
Fentanyl can also be found in opioids prescribed for breakthrough cancer pain in opioid-tolerant patients called Transmucosal immediate-release fentanyls (TIRFs.) TIRFS are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent inappropriate prescriptions of these extremely potent drugs.
A 2020 study by Aventis Pharmaceuticals found that higher doses of naloxone, the opioid overdose-reversing medication, can help resuscitate a victim of an overdose involving synthetic opioids such as carfentanil, a substance that is 100 times as strong as fentanyl. According to Health Crisis Alert, "Researchers gave monkeys the synthetic opioid carfentanil followed by different doses of naloxone. . . . After receiving naloxone, the monkeys’ brains were observed using Positron Emission Tomography imaging. The higher the level of naloxone, the higher the receptor occupancy."
In the US, addiction and overdoses affect mostly non-Hispanic Whites from the working class. Native Americans and Alaska Natives experienced a five-fold increase in opioid-overdose deaths between 1999 and 2015, with Native Americans having the highest increase of any demographic group. There is significant speculation as to the root causes of the demographic differences, but thus far a credible explanation has yet to be found given the complexity of the issue and the difficulty in controlling for variables when investigating.
In 2014, roughly 12 percent of young adults between the ages of 18 and 25 reported abusing prescribed opioids.
In 2016, approximately 91 people died everyday from overdosing on opioids. Roughly half of these deaths were caused by prescribed opioids.
In 2018, the opioid crisis continued to disproportionately affect non-Hispanic Whites and Native Americans with the National Institutes of Health (NIH) reporting a rise in opioid morbidity and opioid related fatalities. This is especially concerning considering the epidemiology of opioid affliction among white women, who are at a greater risk because they receive more prescription medications than men. According to the NIH (2018), "The opioid epidemic is increasingly young, white, and female" with 1.2 million women being diagnosed with an opioid use disorder compared to 0.9 million men in 2015.
In the United States, those living in rural areas of the country have been the hardest hit. Canada is similarly affected, with 90% of cities with the highest hospitalization rates having a population below 225,000. Western Canada has an overdose rate nearly 10 times that of the eastern provinces.
Non-medical prescription drug use rates have been increasing in teenagers with access to parents' medicine cabinets, especially as 12- to 17-year-old girls were one-third of all new users of prescription drugs in 2006. Teens used prescription drugs more than any illicit drug except cannabis, more than cocaine, heroin, and methamphetamine combined. In 2014, roughly 6 percent of teenagers between the ages of 12 and 17 reported abusing prescribed opioids. Deaths from overdose of heroin affect younger people more than deaths from other opiates.
Prescription rates for opioids vary widely across states. In 2012, healthcare providers in the highest-prescribing state wrote almost three times as many opioid prescriptions per person as those in the lowest-prescribing state. Health issues that cause people pain do not vary much from place to place and do not explain this variability in prescribing. Researchers suspect that the variation results from a lack of consensus among elected officials in different states about how much pain medication to prescribe. A higher rate of prescription drug use does not lead to better health outcomes or patient satisfaction, according to studies.
In Palm Beach County, Florida, overdose deaths went from 149 in 2012 to 588 in 2016. In Middletown, Ohio, overdose deaths quadrupled in the 15 years since 2000. In British Columbia, 967 people died of an opiate overdose in 2016, and the Canadian Medical Association expected over 1,500 deaths in 2017. In Pennsylvania, the number of opioid deaths increased 44 percent from 2016 to 2017, with 5,200 deaths in 2017. Governor Tom Wolf declared a state of emergency in response to the crisis.
|State||Opioid prescriptions written||Rank|
|District of Columbia||85.7||23|
The high death rate by overdose, the spread of communicable diseases, and the economic burden are major issues caused by the epidemic, which has emerged as one of the worst drug crises in American history. More than 33,000 people died from overdoses in 2015, nearly equal to the number of deaths from car crashes with deaths from heroin alone more than from gun homicides. It has also left thousands of children suddenly in need of foster care after their parents have died from an overdose.
Addiction does not only affect the people taking the drug but the people around them, like families and relationships. Conflict is usually the number one problem between family members and the people abusing heroin, the fighting becomes an everyday routine. In Jeff Schonberg and Philippe Bourgois's ethnography, Righteous Dopefiend, they did a participant observation from 1994 to 2006, and they focused on the lives of the homeless heroin addicts in San Francisco, California. They found that for example, Sonny is still in contact with his family, but he doesn't live with them, and he vowed to himself that he will never let his family see him at his worst, but he goes to his family usually for holidays and important dates, and when he is with them he is sober. This kind of relationship isn't always the case though. They observed another example with Tina whose parents have completely cut off contact with her, and she is left on the streets with nobody except the family she has created in the homeless society.
A 2016 study showed the cost of prescription opioid overdoses, non-medical use, and dependence in the United States in 2013 was approximately $78.5 billion, most of which was attributed to health care and criminal justice spending, along with lost productivity. By 2015 the epidemic had worsened with overdose and with deaths doubling in the past decade. The White House stated on November 20, 2017 that in 2015 alone the opioid epidemic cost the United States an estimated $504 billion.
Two employees of the University of Notre Dame were killed in a murder-suicide over the refusal of Dr. Todd Graham, 56, to renew the opioid prescription for the wife of Mike Jarvis, 48. United States Representative Jackie Walorski sponsored a bill in the memory of the doctor who would not over-prescribe; the Dr. Todd Graham Pain Management Improvement Act is intended to address the opioid epidemic.
The National Safety Council calculated that the lifetime odds of dying from an opioid overdose (1 in 96) in 2017 were greater than the lifetime odds of dying in an automobile accident (1 in 103) in the United States.
The opioid epidemic, combined with the Patient Protection and Affordable Care Act, has led to a situation called the Florida shuffle, where a drug user moves between drug rehabilitation centers so those centers may bill the user's insurance company.
In one study, a decision analytical model of the US population aged 12 years or older found that "under the status quo, an estimated 484,429 individuals were projected to die of fatal opioid overdose" between 2020 and 2029. However, a combination of "reducing opioid prescribing, increasing naloxone distribution, and expanding treatment for opioid use disorder was associated with an estimated 179,151 lives saved when compared to the status quo."
Treatment and effects during COVID-19 pandemic
After slight decreases in opioid fatalities 2017–2018, overdose deaths in the US increased in 2019, due largely to an increase in non-medical use use of fentanyl. The COVID-19 pandemic's interference into both social safety and health care delivery systems has probably intensified the opioid epidemic. US media, on national, state, and local levels, infer that overdose deaths are increasing. But there is no national reporting system on overdose mortality to confirm these reports. Conclusions on the relationship between increasing overdose fatalities and the COVID-19 pandemic will require more research. Studies, such as those by Wainwright et al. and Ochalek et al. intimate that opioid use and overdose deaths may be increasing, just as reported by the media. But more study is needed.
In addition, the COVID-19 pandemic has marked the start of health care policies that, should they be adopted permanently, could not only lessen the effects of the pandemic on overdoses, but also make overall treatment of opioid use disorder more effective by eliminating obstacles to previously proven therapies for these disorders.
According to the US National Institute on Drug Abuse, the coronavirus disease 2019 (COVID-19) pandemic could hit certain populations, such as those suffering from substance use disorders and especially those with opioid use disorder, particularly hard. For opioid use disorder patients, COVID-19's effects on respiratory and pulmonary health is a significant threat.
According to an April 2020 Health Affairs journal article "Once The Coronavirus Pandemic Subsides, The Opioid Epidemic Will Rage," recommended potential solutions include requiring doctors in large physician groups to get the federal waiver that would allow them to prescribe FDA-approved mediations to treat addiction. Under the Drug Addiction Treatment Act of 2000, physicians can obtain an "X-waiver" to prescribe buprenorphine.
Other studies have looked at treatments for OUD during the COVID-19 pandemic. For example, one JAMA Internal Medicine research letter from December 2020 found that since the COVID-19 national emergency declaration, "the number of individuals filling buprenorphine prescriptions has plateaued but has not decreased; however, filled prescriptions for all medications collectively have decreased considerably."
US federal government
In 2010, the US government began cracking down on pharmacists and doctors who were over-prescribing opioid painkillers. An unintended consequence of this was that those addicted to prescription opiates turned to heroin, a significantly more potent but cheaper opioid, as a substitute. A 2017 survey in Utah of heroin users found about 80 percent started with prescription drugs.
In 2010, the Controlled Substances Act was amended with the Secure and Responsible Drug Disposal Act, which allows pharmacies to accept controlled substances from households or long-term care facilities in their drug disposal programs or "take-back" programs.
In 2011, the federal government released a white paper describing the administration's plan to deal with the crisis. Its concerns have been echoed by numerous medical and government advisory groups around the world. In July 2016, President Barack Obama signed into law the Comprehensive Addiction and Recovery Act, which expands opioid addiction treatment with buprenorphine and authorizes millions of dollars in funding for opioid research and treatment.
In 2016, the US Surgeon General listed statistics which describe the extent of the problem. The House and Senate passed the Ensuring Patient Access and Effective Drug Enforcement Act which was signed into law by President Obama on April 19, 2016, and may have decreased the DEA's ability to intervene in the opioid crisis. In December 2016, the 21st Century Cures Act, which includes $1 billion in state grants to fight the opioid epidemic, was passed by Congress by a wide bipartisan majority (94-5 in the Senate, 392–26 in the House of Representatives), and was signed into law by President Obama.
As of March 2017[update], President Donald Trump appointed a commission on the epidemic, chaired by Governor Chris Christie of New Jersey. On August 10, 2017, President Trump agreed with his commission's report released a few weeks earlier and declared the country's opioid crisis a "national emergency". Trump nominated Representative Tom Marino to be director of the Office of National Drug Control Policy, or "drug czar". One interview in 2015 with the then Director of the White House Office of National Drug Control Policy under the Obama administration, Michael Botticelli, where he states that because opioid users are predominantly 'white and middle class', they "know how to call a legislator, [and] fight with their insurance company."
However, on October 17, 2017, Marino withdrew his nomination after it was reported that his relationship with the drug industry might be a conflict of interest. In July 2017, FDA commissioner Scott Gottlieb stated that for the first time, pharmacists, nurses, and physicians would have training made available on appropriate prescribing of opioid medicines, because opioid addiction had become the "FDA's biggest crisis". Trump nominated his then deputy chief-of-staff, James Carroll as the acting director of the Office of National Drug Control Policy in 2018. Carroll was subsequently approved by the Senate in January 2019.
In April 2017, the Department of Health and Human Services announced their "Opioid Strategy" consisting of five aims:
- Improve access to prevention, treatment, and recovery support services to prevent the health, social, and economic consequences associated with opioid addiction and to enable individuals to achieve long-term recovery;
- Target the availability and distribution of overdose-reversing drugs to ensure the broad provision of these drugs to people likely to experience or respond to an overdose, with a particular focus on targeting high-risk populations;
- Strengthen public health data reporting and collection to improve the timeliness and specificity of data and to inform a real-time public health response as the epidemic evolves;
- Support cutting-edge research that advances our understanding of pain and addiction, leads to the development of new treatments, and identifies effective public health interventions to reduce opioid-related health harms; and
- Advance the practice of pain management to enable access to high-quality, evidence-based pain care that reduces the burden of pain for individuals, families, and society while also reducing the inappropriate use of opioids and opioid-related harms.
The US Food and Drug Administration (FDA) has taken another approach to this epidemic: requiring manufacturers of long-acting opioids to sponsor educational programs for prescribers. The FDA hoped that these educational programs would help deter off-label and over-prescribing; however, it is still unclear if these programs truly have a positive effect on reducing opioid prescriptions. In March 2019, two FDA specialists publicly demanded that the FDA suspend new opioid approvals, alleging that the FDA's oversight of opioid approvals had been dangerously deficient.
The Substance Abuse and Mental Health Services Administration administers the Opioid State Targeted Response grants, a two-year program authorized by the 21st Century Cures Act which provided $485 million to states and US territories in the fiscal year 2017 for the purpose of preventing and combatting opioid misuse and addiction.
Dr. Thomas Frieden, former director of the Centers for Disease Control and Prevention, said that "America is awash in opioids; urgent action is critical." The crisis has changed moral, social, and cultural resistance to street drug alternatives such as heroin. Many state governors have declared a "state of emergency" to combat the opioid epidemic or undertook other major efforts against it. In July 2017, opioid addiction was cited as the "FDA's biggest crisis". In October 2017, President Donald Trump concurred with his Commission's report and declared the country's opioid crisis a "public health emergency". Federal and state interventions are working on employing health information technology in order to expand the impact of existing drug monitoring programs. Recent research shows promising results in mortality and morbidity reductions when a state integrates drug monitoring programs with health information technologies and shares data through centralized platform.
The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act was introduced by the US House of Representatives on June 22, 2018, and was advanced on June 22, 2018. The bill includes Medicare and Medicaid reform in order to improve treatment, recovery, and prevention efforts while also strengthening the fight against synthetic drugs like fentanyl.
On September 17, 2018, the US Senate approved the SUPPORT for Patients and Communities Act (H.R. 6). The committee reached a final agreement on terms of the bill on September 25, 2018. The final agreement included provisions from multiple other acts, such as The Opioid Crisis Response Act of 2018, The Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, and the Synthetics Trafficking and Overdose Prevention (STOP) Act of 2018. The House and The Senate passed the final draft on September 28 and October 3, respectively. President Donald Trump signed the package into law on October 28, 2018.
In July 2019, English multinational consumer goods corporation Reckitt Benckiser, parent of US pharmaceutical company Indivior, agreed to pay $1.4 billion to the U.S. Department of Justice and the Federal Trade Commission to resolve false marketing claims about the effectiveness of its opioid addiction drug, Suboxone, and to resolve charges over their scheme to direct patients towards doctors who were likely to prescribe Suboxone.
In September 2019, President Trump issued an executive order to block shipments of fentanyl and counterfeit goods from other countries, where illegal distributors were using regular mail for deliveries. While China was a focus for the action, the order included any nation where it was either manufactured or shipped from. Trump claimed that the Chinese government had not done enough to stop the smuggling of fentanyl manufactured there:
I am ordering all carriers, including FedEx, Amazon, UPS and the Post Office, to search for and refuse all deliveries of fentanyl from China (or anywhere else!). Fentanyl kills 100,000 Americans a year. President Xi said this would stop – it didn’t.
In July 2020, Indivior Solutions, Indivior Inc., and Indivior plc agreed to pay $600 million to resolve liability related to false marketing of Suboxone to MassHealth for use by patients with children under the age of six years old. Additionally, Indivior Solutions pled guilty to one-count of felony information.
State and local governments
In response to the surging opioid prescription rates by health care providers that contributed to the opioid epidemic, US states began passing legislation to stifle high-risk prescribing practices (such as prescribing high doses of opioids or prescribing opioids long-term). These new laws fell primarily into one of the following four categories:
- Prescription Drug Monitoring Program (PDMP) enrollment laws: prescribers must enroll in their state's PDMP, an electronic database containing a record of all patients' controlled substance prescriptions
- PDMP query laws: prescribers must check the PDMP before prescribing an opioid
- Opioid prescribing cap laws: opioid prescriptions cannot exceed designated doses or durations
- Pill mill laws: pain clinics are closely regulated and monitored to minimize the prescription of opioids non-medically
In July 2016, governors from 45 US states and 3 territories entered into an interstate compact titled a "Compact to Fight Opioid Addiction" organized by Massachusetts Governor Charlie Baker where they agreed to adopt the strategies for addressing the opioid epidemic modeled after the policies implemented in Massachusetts. They agreed that collective action would be needed to end the opioid crisis, and they would coordinate their responses across all levels of government and the private sector, including opioid manufacturers and doctors.
In 2017 Alabama had the highest overall opioid prescribing rate in the US. The University of Alabama – Birmingham has made a commitment to battle the opioid epidemic. UAB's “Addiction Scholars Program” trains health care professionals - doctors, nurses, therapists, and social workers with insights into addiction in a 15-month course. The UAB School of Nursing offers “Nursing Competency Suites” with training on treating infants born to opioid-addicted mothers. The university also began an “Opioid Stewardship Committee” to “…consistently and frequently address opioid stewardship.”
Opioid data for Alabama indicated that, from 2006 to 2014 2.3 billion pain pills were prescribed in the state. McKesson Corporation distributed 728 million of these pain pills; Par Pharmaceutical manufactured 713 million. The highest number of the pills went to Senior Care Pharmacy in Northport AL.
Arizona's Governor Doug Ducey signed the Arizona Opioid Epidemic Act on January 26, 2018, to confront the state's opioid crisis. In Maricopa County which includes Phoenix, 3,114 overdoses were reported from June 15, 2017, through January 11, 2018. The law provides $10 million for treatment and limits an initial opioid prescription to five days with some exemptions. Arizona also implemented a new strategy of prescription drug monitoring programs in 2017. Since then, the number of opioid prescriptions filled has dropped nearly forty percent, while the number of opioid prescriptions written has dropped forty-three percent (King, 2018). The reductions in these numbers both show Arizona going in the right direction, although, even with the decrease, the number of deaths and overdoses continue to rise.
In October 2016, the state began the Arkansas Naloxone Project, a partnership of the State Drug Director's Office, DHS, and the Criminal Justice Institute (CJI) to allocate kits containing the nasal spray Narcan to first responders, schools, libraries, as well as drug treatment and recovery agencies to reverse the effects of opioid overdose. The project, funded by federal grants and the Arkansas Blue & You Foundation, distributed 7,000 kits and provided training to 8,000 individuals. Additionally, the Drug Director's Office and the CJI developed an app, nARcansas, a free opioid overdose training vehicle that shows how to administer the life-saving antidote and provide other information about opioids and overdoses, in both English or Spanish versions. The project has saved lives in almost half of Arkansas’ 75 counties, with the most success in Pulaski County, the state's most populated.
In California, SB 482 took effect on October 2, 2018, requiring doctors and other healthcare professionals to check the Controlled Substance Utilization Review and Evaluation System, also known as CURES, before issuing any opioid prescriptions. SB 1109 was signed by Governor Jerry Brown in September 2018 (to take effect on January 1, 2019), requiring certain healthcare professionals undergo mandatory continuing education courses on the risk of addiction with opioids. In addition, this law would require outpatient pharmacies to apply warning labeling on all opioid prescription bottles cautioning patients of the risk of overdose and addiction associated with the drug. SB 1109 also targets vulnerable populations like students, requiring schools to provide students participating in youth sports or athletic programs with the CDC's Opioid Factsheet for Patients, that again address the risks of opioid use. In 2019, the city of San Francisco began a program called the Drug Overdose Prevention & Education (DOPE) Project, which trains individuals with substance use disorder, their families or anyone who may live in their communities who wants to help people suffering from overdoses. The DOPE Project, the largest single city naloxone-distribution effort in the US, instructs its advocates in the use of the nasal spray Narcan (Naloxone), an opioid reversal antidote. The group, able to save nearly 1,800 overdosing people in 2019, is currently challenged by the rise in fentanyl and methamphetamine use.
Overdose death from the drug fentanyl increased by 300% from 2018 to 2019, according to the Denver Department of Public Health and Environment. Overall death from all drug overdoses increased slightly over the same time period. Denver has created an “early warning system” to let drug rehab organizations know if fentanyl has been found in the area's recreational drug supply. The Harm Reduction Action Center, one of those organizations, provides substance users with a needle exchange and fentanyl-testing strips. In 2016, then Colorado Attorney General Cynthia Coffman launched the Naloxone for Life Initiative which initially distributed 7,000 naloxone kits around the state. The state medical director then issued an order to make the drug available without prescription. Applying the drug has been successful. Denver's paramedics administered the opioid-overdose reversal drug to over 700 individuals in 2018. Colorado experienced a small decrease in opioid overdose deaths between 2017 and 2018.
In 2019 there were 1,200 opioid deaths in the state, a figure that will be reached shortly as 2020 has seen a 22% increase in opioid overdose mortality. The isolation of the COVID-19 pandemic, compounded by personal financial and other anxieties, has caused intense difficulty for people coping with addiction disorders as well as depression. Most traditional businesses have been affected by the pandemic, and the narcotic channel has remained active.
Delaware, which has the 12th-highest overdose death rate in the US, introduced bills to limit doctors' ability to over-prescribe painkillers and improve access to treatment. In 2015, 228 people had died from overdose, which increased 35%—to 308—in 2016.
District of Columbia
The District began a program of free distribution of the nasal spray naloxone (Narcan) in 2018 with 17 locations dispensing the non-injection overdose-reversing drug. In 2020, due to a 50% increase in opioid overdose deaths, the District doubled the distribution to 35 locations in every ward throughout the city. The death statistics from D.C.’s Office of the Chief Medical Examiner are grim: 75% of overdose mortality are individuals 40-69, 70% are male, 84% are Black.
In 2011, Florida passed a law creating a program that would provide monitoring and enforcement against illegal diversion of prescription pills in Florida (sometimes called the "Flamingo Express"). The law had not yet been enacted when Governor Rick Scott took office, and Scott proposed to repeal it before it came into practice. Scott told reporters the program "had no state funding, is complicated by contract challenges, is unproven and could infringe on innocent people’s privacy."
The isolation accompanying the COVID-19 pandemic is hurting Georgians with opioid use disorder. Nationwide, overdoses of opioids jumped 42% in May 2020, according to the Overdose Detection Mapping Application Program, a United States government operation that tracks data from hospitals, ambulance, and police reports. The Georgia Council on Substance Abuse advised all first responders in the state to carry and be conversant with the administration of Narcan “…at all times.” The nasal version of naloxone is critical for first responders during the pandemic as it can be dispensed at arm's length very quickly. The council further brought forth a substantial increase in Emergency Department visits due to opioid overdose. Because of the COVID-19 pandemic, individuals, they said, are missing personal counseling and 12-step meetings. The group also stated that calls to its CARES Warm line grew by 65 percent in three months with a higher intensity than ever experienced.
In 2020, the Overdose Detection Mapping Program noted an 18% increase in opioid overdoses, prompting the US Department of Health and Human Services (HHS) to provide Hawaii with a $2 million (US) grant to increase opioid use disorder treatments. The grant will be divided between the Hawaii State Rural Health Association and the West Hawaii Community Health Center to develop new addiction therapy programs or grow access to existing initiatives.
The 2020 coronavirus pandemic resulted in a crisis within a crisis in Chicago as opioid overdose mortality doubled in the first five months of the year, compared to 2019 from 416 deaths to 924. Overdose deaths increased throughout the state, with the largest upturn in Cook County. Fentanyl, usually combined with heroin, was the drug at the center of 81% of the deaths, up from 74% in 2019.
Indiana has been one of the states seriously affected by the epidemic. In 2015, 1,600 people died from drug overdose; 1,000 of those deaths were opioid-related. By 2017, opioid-related deaths had increased to over 1,200, followed by a small, measured decline since then. In 2018, drug overdose deaths fell 12.9%, almost three times the US average decline, as the state government focused on evidence-based, transformative programs to continue the decline. In 2020, SAMSHA provided a $1 million grant to the state of Indiana and its Social Services Administration to distribute the nasal spray Narcan (naloxone) to individuals in the state whom the ISSA determined were at risk from opioid overdose.
The Chief of Police of Lawrence, IN, (pop.40,000) ordered his officers to cease the administration of the opioid antagonist nasal spray Narcan during the Coronavirus pandemic, fearing that his first responders risk COVID-19 infection exposure by dispensing the intra-nasal drug. The Indiana Department of Homeland Security rejected the chief's order as not being evidence-based and encouraged the administration of the drug by the city's police. A near-by city, Ft. Wayne's (pop.267,000), police continue to disburse the drug which resulted in 233 individuals restored by Narcan in the first quarter 2020.
In September 2017, Kansas received over $500,000 to implement programs and changes to help stop the opioid epidemic. A majority of the money went to drug courts to help prevent crimes and intervene with addicts early on.
The 2020 COVID-19 pandemic has contributed to a significant increase in drug overdose in Kentucky as the state's second largest county, Fayette, witnessed overdose increases of over 40% in the first few months of the year. The county does have an anti-overdose program which, over five years, has distributed over 8,000 naloxone doses. Additionally, the state monitors drug overdose through its Kentucky Overdose Data to Action (KyOD2A) program run by the Department for Public Health, collecting raw data and linking those in need of treatment with available centers as well as supporting community interventions as needed. KyOD2A also partners with the state's prescription electronic reporting system to monitor opioid prescriptions.
In 2017, the Louisiana Department of Health documented an increase in opioid overdoses. Respondents to the state's HIDTA Drug Treatment and Prevention Survey reported high levels of fentanyl use and an 83% increase of inpatient admissions for fentanyl and other opioids. In response to the growing epidemic in Louisiana, the Advisory Council on Heroin and Opioid Prevention and Education, also known as the HOPE Council, was created as an effort to combat opioid use and established a health surveillance and data collection strategy through interagency coordination. In 2019, the Louisiana Comprehensive Opioid Abuse Program Action Plan and the Louisiana's Opioid Response Plan 2019 were released. These types of efforts, however, have been hindered by continued opioid overprescription. In 2018, Louisiana providers wrote 79.4 opioid prescriptions for every 100 persons, compared to the average U.S. rate of 51.4 prescriptions, making Louisiana among the top five of opioid prescribers in the U.S. that year. In New Orleans, NOLA Ready, the City of New Orleans emergency preparedness campaign, sponsors a 1-hour training with the New Orleans Health Department where the general public can learn how to identify an overdose and administer Naloxone. The New Orleans Public Library (NOPL) has also responded by training librarians and the public on opioid prevention and overdose treatment.
Opioid overdose mortality grew by over 90% in some parishes in Louisiana due to the coronavirus pandemic which has affected the capacity of many state residents to remain drug-free. State officials feared this would lead to still more overdose-related deaths and a long-term effect of more addiction-related disease, ushering in more homelessness and family-alienation. On the reverse of that phenomena, state experts fear that those with substance use disorder are more vulnerable to COVID-19 due to damaged lungs and respiratory systems causing a higher rate of infection. Added to that is the fact that those individuals are affected by stay-at-home orders, where they are more likely to succumb the temptation of use and overdose. There are many social services groups, like Capital Area Human Services, providing therapy as well as opioid-reversal drugs; and No Overdose Baton Rouge, which offers clean syringes, the opioid antagonist nasal spray Narcan, and sterile smoking devices, attempting to help.
In March 2017, the governor of Maryland declared a state of emergency to combat the rapid increase in overdoses by increasing and speeding up coordination between the state and local jurisdictions. The previous year about 2,000 people in the state had died from opioid overdoses.
Boston Medical Center has changed its approach to addiction and overdose treatment, due to the pandemic. It now offers telehealth appointments which officials believe are more effective than tradition in-person treatment, as more people are participating. Additionally patients are able to get doses of methadone and addiction medications like buprenorphine without an in-person visit. The state's Department of Public Health indicated that there was a downturn in total overdose deaths in the first quarter of 2020 but that rates of overdose mortality among Black men and women, as well as Hispanic men's overdose incidents, showed a notable increase. A COVID-19 Rapid Response Fund disbursed grants to nonprofits serving opioid addiction sufferers and the Boston Resiliency Fund awarded $500K to similar groups.
A similar plan was created in Michigan, when the state introduced the Michigan Automated Prescription System (MAPS), allowing doctors to check when and what painkillers had already been prescribed to a patient, and thereby help keep addicts from switching doctors to receive drugs.
In December 2019, the National Council on Alcoholism and Drug Abuse (NCADA-STL) reported that St. Louis had a new high of opioid overdose deaths at 1018. When the COVID-19 pandemic occurred three months later, it impacted opioid overdoses incidents significantly, particularly among the Black community in North St. Louis County, North St. Louis City and parts of South City. Combatting the intersecting outbreaks, local Federally Qualified Health Centers (FQHC) have combined to provide simultaneous Narcan, nasal spray naloxone, an opioid antagonist, and increased access to COVID-19 resting.
By May 2020, Nevada experienced a 23% increase in opioid overdose deaths, when compared to 2019. Overdose deaths in the state peaked in 2011 but were on the decline ever since, until 2020. Over half those deaths involved fentanyl. The Nevada Overdose to Action program reported it was difficult to ascribe the increase to the COVID-19 pandemic, but, like health care providers across the country, the group felt that the isolation and stress caused by the pandemic contributed to the increase in mortality.
The Overdose Mapping Application Program, developed by University of Baltimore, has reported an increase in overdose-related mortality, particularly in southern Nevada. The deaths, thought to be connected to individuals ingesting opioids when isolated, can be prevented with the use of the opioid antagonist Narcan as recommended by the Southern Nevada Health District.
The state suffered 3021 drug-related deaths in 2019 when 3.99 million opioid prescriptions were dispensed, down slightly from 3102 in 2018 when 4.3 million opioid prescriptions were filled. In the first quarter 2020, drug-related deaths were 789. The coronavirus pandemic has overshadowed another, longer term crisis in the state – the opioid epidemic. Detox centers have cut down on accepting patients, people in 12-step programs must meet online, and individuals who successfully complete rehab face more hurdles – unemployment and homelessness. “It’s almost like everything has been stopped in time,” said John Pellicane, Director of the Office of Mental Health and Addiction Awareness Task Force in Camden County, New Jersey. Phone calls to the state's addiction hotline, ReachNJ, increased from an average 3,500/month to 4,000/month. Morris County overdoses increased by 41% in first quarter 2020. There were 100 more overdose deaths in the same period – statewide. Bergen County suspended all face-to-face substance use disorder counseling and meetings. The state does not approve of virtual meetings or counseling due to confidentiality concerns and trust issues.
In 2020, New Jersey Attorney General Gurbir Grewal announced that, during the COVID-19 pandemic, all medical personnel were required to prescribe the opioid antagonist naloxone (nasal spray Narcan) to individuals ingesting higher doses of opioids or those combining opioids with benzodiazepines, such as Xanax, an anti-anxiety medication. This regulation, already in the process of being recommended by various state entities, was adopted quickly in response to the coronavirus pandemic and a concomitant increase in overdose mortality. First responders also reported an increase in dispensing Narcan to those suffering from overdoses. It was thought that providing Narcan to individuals whose prescriptions were the equivalent or 90 morphine milligrams would free medical emergency workers and police from responding to overdose exigencies. By May 2020, Gov. Phil Murphy's administration reported that mortality from opioid overdoses had increased 20%. To counter the trend, the state sent 11,000 doses of the nasal spray naloxone. The first shipment went to 178 emergency medical service teams across the state.
The New York State Department of Health reported that the Office of National Drug Control Policy wanted to use New York's police training policy on opioids as a model for other states. Additionally, in 2019 NYSDOH began the NY State Opioid Data Dashboard, which provides datapoints to educate local opioid-prevention officials and policy makers on the epidemic. The dashboard includes quarterly updates on opioid overdose information like mortality, ED visits and hospitalization by county throughout the state. NYSDOH also developed I-Stop, a requirement for all prescription-providing health care professionals to report and track their prescriptions for controlled substance drugs, thereby stemming patients from seeing many doctors for prescriptions. The combination of the COVID-19 pandemic and the opioid crisis causes unique problems for recovering addicts who rely on community support in a time of social distancing. A Binghamton NY addiction resource center, Truth Pharm, has revamped its Narcan (Naloxone) training to a virtual model. Additionally, even virtual Narcan training can be more than simply administering a life-saving drug as it provides those struggling with addiction a human contact and the ability to discuss specific needs and issues.
In 2020, there was a 25.8% increase in opioid overdose cases and a 38% increase in overdose deaths in the Rochester area (Monroe County). Concern over the overdose growth has led to legislators introducing legislation in the state Assembly that would require pharmacies to offer a dose of Narcan (naloxone) to individuals receiving an opioid prescription. Narcan is presently available in New York state without a prescription. The new legislation provides funding for the payment of co-pays or free Narcan if the individual has no insurance.
At 24.6 deaths per 1,000 people, Ohio has the 5th highest rate of drug overdose deaths in the United States. The Governor's Cabinet Opiate Action Team (GCOAT) was created in 2011 by Governor John Kasich and is "one of the nation's most aggressive and comprehensive approaches to address opioid use disorder and overdose deaths, including a strong focus on preventing the nonmedical use of prescription drugs". GCOAT utilizes partnerships with various state agencies including the Ohio Board of Pharmacy. The strategy suggests regulations that are encompassed under three main categories: (1) to promote the responsible use of opioids, (2) to reduce the supply of opioids, and (3) to support overdose prevention and expand access to naloxone. The legislation reduced the number of opioid doses by over 80 million between 2011 and 2015. Also, unintentional drug related overdose deaths involving prescription opioids have decreased from 45% in 2011 to 22% in 2015. However, Ohio has not seen a decrease in fentanyl distribution. The coronavirus pandemic of 2020 reduced treatments for those suffering from substance use disorders in many Ohio counties, leading to increases in drug overdoses. For example, Highland County experienced double the amount of drug overdose calls to the sheriff's department from May 2019 to May 2020. The number of overdoses in Franklin County increased by 50% in the first four months of 2020.
The city of Philadelphia suffers from the highest rate (among all US big cities) of drug overdose in the country, averaging three mortalities per day in 2019, a situation intensified by the 2020 coronavirus pandemic. Prevention Point Philadelphia, the US's largest syringe-exchange organization, doubled the amount of the nasal spray Narcan (naloxone) it distributed in the first month of the city's stay-at-home order. The city's overdose mortality rated remained the same as it was pre-pandemic, providing an indication that more Narcan was being administered to overdose victims. Several Philadelphia-based public health and criminal justice support groups were providing cell phones to homeless people and inmates recently released from prison so they can experience telehealth healthcare provider visits and renew prescriptions for opioid antagonist medication. The Pennsylvania Harm Reduction Coalition (PAHRC) initiated a new postal service-based naloxone distribution program that delivers the drug directly to the home. The group also included PPE gloves and face shields with the naloxone kits in an attempt to limit coronavirus dispersal.
Beaver County PA, after experiencing a decline in opioid overdose deaths from 2017, saw a 30% increase in those deaths since the pandemic began, according to UPMC Western Psychiatric Hospital addiction medicine services. The county also suffered from an increase in domestic violence, child abuse, and worsening drug and alcohol use disorder, all attributed to the isolation caused by the pandemic.
The state suffered 1,103 overdose fatalities in 2018. In 2020, state substance use disorder remedial facilities were concerned about the impact of COVID-19. They emphasized the importance of group meetings; several have moved the meetings outside. The Phoenix Center, in Greenville, limited large meetings and restricted visitor access to its in-patients. Other providers have turned to on-line meetings, but participation is down. The South Carolina Department of Alcohol and Other Drug Abuse Services (SC DAODAS), concerned about the effects of the coronavirus pandemic on state residents suffering from substance use disorder, fears a setback in its battle with the opioid epidemic. The apprehension that self-quarantining and the isolation it brings can cause loneliness, anxiety, boredom, clinical depression or PTSD can lead to enhanced overdose risk. In April 2020, the department provided over 7,000 boxes of Narcan (Naloxone), the nasal spray overdose reversal drug while encouraging afflicted South Carolinians to take advantage of the DAODAS’ system of state-licensed and nationally accredited service providers. The department also encouraged individuals to reach out to friends and family during this crisis.
Carter County, Tennessee, population 56K, has experienced nearly 60 opioid overdose deaths since 2014, a year in which 8.1 million opioid prescriptions were written in the entire state, population 6.5 million. To stem that consequence of addiction, the county's drug prevention alliance embarked on a controversial policy – providing Narcan distribution training to around 600 children and teenagers. Some of the children have taught what they learned to their peers and distributed Narcan at community events where one child handed out 70 doses of the drug. The region is a conservative one where residents, law enforcement and school boards have objected, considering Narcan a “waste of resources” and the training not child-appropriate.
A spike in overdoses and overdose deaths due to the COVID-19 pandemic led Memphis-area Baptist Hospitals and Integrated Addiction Care (IAC), an outpatient rehab group, to set up a 24/7 hotline for individuals struggling with addiction. The Shelby County Health Department stated that people with substance use disorder issues should have access to both the care they need and to Narcan, the nasal spray opioid antagonist. The free hotline is staffed by physician professionals who can provide medical advice or direct callers to an emergency department.
Studies have found that after the implementation of "pill mill laws" in Texas, opioid dose, volume, prescriptions and pills dispensed within the state were all significantly reduced.
The number of opioid overdoses in Burlington VT increased by 76% in 2020; the number of nonfatal overdose emergency room visits went up 100% in the same period, according to Burlington's police department. But the number of overdose fatalities went down for the first time since 2014. The overdose increases are due to an influx of fentanyl, a synthetic opioid, as well as the pressures of the COVID-19 pandemic; the mortality decreases are the result of safety measures, such as the community distribution of Narcan, a nasal spray used to reverse an overdose.
The state of Wisconsin established the HOPE (Heroin, Opiate Prevention and Education) agenda to face the Opioid Epidemic. The Enactment of Act 262 took place on April 9, 2018. The act focuses on bettering substance use disorder counseling, which is critical in the opioid withdrawal process.
In 2017, Rep. Edward H. Redd and Sen. Todd Weiler proposed amendments to Utah's involuntary commitment statutes which would allow relatives to petition a court to mandate substance-abuse treatment for adults.
In February 2017, officials in Everett, Washington, filed a lawsuit against Purdue Pharma, the manufacturer of OxyContin, for negligence by first, allowing and also failing to prevent drugs being illegally trafficked to city residents. The city wants the company to pay the costs of handling the crisis.
In West Virginia, leading the nation in overdose deaths per capita, lawsuits sought to declare drug distribution companies a "public nuisance" in an effort to place accountability upon the drug industry for the costs associated with the epidemic. On May 3, 2021, the city of Huntington, West Virgina filed a lawsuit against three major drug manufacturers accusing them of their role in stoking the opioid crisis through their excessive shipment of painkillers.
In May 2019, in the first successful prosecution of top pharmaceutical executives for crimes related to the prescribing of opioids, the founder and four former executives of Insys Therapeutics Inc. were convicted by a federal jury in Boston in connection with bribing medical practitioners to prescribe Subsys, a highly-addictive sublingual fentanyl spray intended for cancer patients experiencing breakthrough pain, and for defrauding Medicare and private insurance carriers. The company declared bankruptcy about two weeks after they lost the case.
Dozens of states are suing pharmaceutical companies, accusing them of causing the epidemic. Suits filed by almost 2,000 cities, counties, and tribal lands have been rolled into a single federal case scheduled to be heard in Fall 2019. In the first state case to reach a decision, on August 26, 2019 Oklahoma district court judge Thad Balkman found the pharmaceutical company Johnson & Johnson responsible for creating a "public nuisance" under state law, and ordered the company to pay a fine of $572 million. The company said they will appeal. Two other drug makers had previously settled with the state of Oklahoma. Purdue Pharma, the maker of OxyContin, agreed to a fine of $270 million in March 2019, and Teva Pharmaceuticals, which makes generic drugs, agreed to pay $85 million in May.
States reject distributors’ settlement
In February 2020, 21 US states turned down an $18 billion (US), 18-year offer from McKesson, Cardinal Health Inc. and AmerisourceBergen Corp. that would have resolved litigation against the pharmaceutical companies over their distribution of the addictive painkillers. A letter from the attorneys general of Ohio, Florida and Connecticut (among others) said the settlement, as “currently structured,” was not acceptable to the states. This particular offer was part of the proposed $50 billion (US) agreement to find a resolution to over 2,000 lawsuits from both local and state governments attempting to recoup billions of dollars they have spent combatting the crisis.
July 2021 settlement
Four major drug manufacturers and distributors, J&J, McKesson, Cardinal Health, and AmerisourceBergen, have agreed to a settlement announced by a group of state attorneys general in July 2021. The settlement, $26 billion (US), will be used on the prevention of opioid addiction and treatment programs. J&J will pay $5 billion (US) over the next five years; the remaining $21 billion (US) will be paid by the other firms. The settlement, when approved by a "significant" group of states and local governments, will settle more than 4,000 individual legal actions. All four of the manufacturing firms disputed all allegations in the lawsuits.
The United States’ three largest pharmaceutical distributors, AmerisourceBergen, Cardinal Health and McKesson reached an agreement in October 2019 where they will pay two Ohio counties a combined US$215 million. As part of the deal, Israel drug manufacturer Teva will also provide US$20 million in cash and US$25 million worth of Suboxone, an opioid addiction treatment. Cuyahoga County (Cleveland) and Summit County (Akron) brought the suit in US Federal District Court (Northern District of Ohio). The settlement averted what would have been the first federal trial over the US opioid crisis. The defendants offered no admission of wrongdoing.
More than 2,600 lawsuits against the US pharmaceutical industry are still in the offing. The plaintiffs in those cases said the Ohio settlement allows them time to attempt to negotiate a national settlement. It also pressures the participants to work out a deal, as every partial settlement diminishes the aggregate total the companies will be able to pay.
Homicide by overdose
Homicide by overdose is the act of giving someone a specified controlled substance which causes that person to die. They are considered an easy way to murder an addict as no one will suspect it's anything but a routine overdose. However states are charging people even when the overdose was unintentional.
As of 2019, half of all US states have "homicide-by-overdose" or "drug-induced homicide" (DIH) laws. While these laws date back to the 1980s, they were originally used infrequently. Prosecutions dramatically increased in the 21st century. (In 2000, there were 2 prosecutions; in 2017, there were 717 prosecutions.) In 2017, legislators in at least 13 states introduced bills to enhance these laws or create new ones.
Prescription drug monitoring
In 2016, the CDC published its "Guideline for Prescribing Opioids for Chronic Pain", recommending opioids only be used when benefits for pain and function are expected to outweigh risks, and then used at the lowest effective dosage, with avoidance of concurrent opioid and benzodiazepine use whenever possible. Silvia Martins, an epidemiologist at Columbia University, has suggested getting out more information about the risks:
The greater "social acceptance" for using these medications (versus illegal substances) and the misconception that they are "safe" may be contributing factors to their misuse.
Hence, a major target for intervention is the general public, including parents and youth, who must be better informed about the negative consequences of sharing with others medications prescribed for their own ailments. Equally important is the improved training of medical practitioners and their staff to better recognize patients at potential risk of developing nonmedical use, and to consider potential alternative treatments as well as closely monitor the medications they dispense to these patients. As of April 2017, prescription drug monitoring programs (PDMPs) exist in every state. A person on opioids for more than three months has a 15-fold (1,500%) greater chance of becoming addicted.
The CDC's "Guideline for Prescribing Opioids for Chronic Pain" offers many non-pharmacological options as alternatives to prescribing opioids. Physical therapist interventions is an example that is offered in regards to an alternative to prescribing opioids.
PDMPs allow pharmacists and prescribers to access patients' prescription histories to identify suspicious use. However, a survey of US physicians published in 2015 found only 53% of doctors used these programs, while 22% were not aware these programs were available. Following the implementation of pill mill laws and prescription drug monitoring programs in Florida, there was a large decline in opioid prescriptions written by high-risk prescribers (those prescribing the top 5th of opioids by volume). The Centers for Disease Control and Prevention (CDC) was tasked with establishing and publishing a new guideline, and was heavily lobbied.
A 2018 study by the University of Florida concluded that there is little evidence that drug-monitoring databases are having a positive effect on the number of drug overdoses in the US. Researcher Chris Delcher also concluded that "there was a concurrent rise in fatal overdoses from fentanyl, heroin and morphine" due to ease of availability and lower cost following prescription drug crackdowns.
- Register and use state prescription drug monitoring programs
- Enhance education and training
- Support comprehensive treatment for pain and substance use disorders
- Help end stigma
- Co-prescribe naloxone to patients at risk of overdose
- Encourage safe storage and disposal of opioids and all medications.
The Opioid Task Force 2018 Progress Report states that between 2013 and 2017 opioid prescriptions have decreased by 22.2%, which includes a 9% decrease from 2016 to 2017 alone. The AMA Opioid Task Force also reports a 389% increase in physician participation in PDMPs. Further, physicians are encouraged to co-prescribe naloxone to those at risk of overdose. In 2017 alone, weekly filled naloxone prescriptions have doubled from 3,500 to 8,000 and more than 50,000 physicians were certified in 2017 to provide in-office buprenorphine. Patrice A. Harris, chair of the AMA Opioid Task Force, urges increased participation by physicians, saying "what is needed now is a concerted effort to greatly expand access to high quality care for pain and for substance use disorders. Unless and until we do that, this epidemic will not end."
In the media
Media coverage has largely focused on law-enforcement solutions to the epidemic, which portray the issue as criminal, whereas some see it as a medical issue. There has been differential reporting on how white suburban or rural addicts of opioids are portrayed compared to black and Hispanic urban addicts, often of heroin, reinforcing stereotypes of drug users and drug-using offenders. In newspapers, white addicts' stories are often given more space, allowing for a longer backstory explaining how they became addicted, and what potential they had before using drugs. In early 2016 the national desk of The Washington Post began an investigation with assistance from fired Drug Enforcement Administration regulator Joseph Razzazzisi on the rapidly increasing numbers of opioid related deaths.
While media coverage has focused more heavily on overdoses among whites, use among African, Hispanic and Native Americans has increased at similar rates. Deaths by overdose among white, black, and Native Americans increased by 200–300% from 2010 to 2014. During this time period, overdoses among Hispanics increased 140%, and the data available on overdoses by Asians was not comprehensive enough to draw a conclusion.
In August 2014, the website Annals of Emergency Medicine collaborated with the Academic Life in Emergency Medicine (ALiEM) and posted a discussion board about the opioid epidemic. The discussion acquired a little over 1000 readers and lasted roughly 14 days. There were four questions posted on the discussion that encouraged readers to share their opinions on how opioids should be prescribed and used.
In July 2019 the Washington Post and the Charleston (WV) Gazette-Mail gained a court order after a year-long battle with the Drug Enforcement Administration (DEA). The order allowed the Post access to the DEA Automation of Reports and Consolidated Orders System (ARCOS), a system that traces the manufacture, distribution and retail sale of every pain pill in the US. The Post's analysis of the data indicated 76 billion oxycodone and hydrocodone pain pills were distributed throughout the US 2006–2012. 57 billion (75%) of these pain pills were distributed by these companies: McKesson Corp., Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart. Nearly 67 billion (88%) of the drugs were manufactured by SpecGx, a subsidiary of Mallinckrodt; Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals. The greatest number of pills/person were found in West Virginia – 66.5; Kentucky – 63.3; Tennessee – 57.7; and Nevada – 54.7. The highest opioid overdose rate 2006-2012 was in West Virginia. Rural communities were hit particularly hard. 306 pills/person/year were shipped to Norton VA; 242 to Martinsville VA; 203 the Mingo County WV; and 175 to Perry County KY.
The opioid epidemic is often discussed in terms of prevention, but helping those who are already addicted is addressed less frequently. Opioid dependence can lead to a number of consequences like contraction of HIV and overdose. For addicted persons who wish to treat their addiction, there are two classes of treatment options available: medical and behavioral. Neither is guaranteed to successfully treat opioid addiction. Which treatment, or combination of treatments, is most effective varies from person to person.
These treatments are doctor-prescribed and -regulated, but differ in their treatment mechanism. Popular treatments include kratom, naloxone, methadone, and buprenorphine, which are more effective when combined with a form of behavioral treatment.
Accessing treatment, however, can be difficult. The strict regulation of opioid treatment programs dates back to the early 20th century. Before 1919, physicians prescribed milder forms of opiates to help wean patients off opium. In Webb v. United States, the Supreme Court ruled that doctors could no longer prescribe narcotics to aid in treating a narcotic use disorder. Thus, morphine dispensaries emerged in communities to fill the treatment gap and were the early precedents to modern methadone clinics.
It is still difficult for providers to prescribe opioids for medication-assisted treatment despite the data that show individuals addicted to opioids have better outcomes with that than abstinence-based treatment programs. Programs are required to be accredited by SAMHSA or the Drug Enforcement Administration which is a lengthy, time- and resource-consuming process including intensive training and site visit reviews. To stay in operation, they must submit to re-accreditation every 1–3 years.
Accredited programs are also able to administer buprenorphine, provided that those prescribing and administering the drug have completed the 8–24 hours of SAMHSA training. Office-based physicians who wish to prescribe buprenorphine for the treatment of opioid use disorder must also complete the required training, as well as apply for and receive a waiver from SAMHSA. Under regulation, physicians may not have more than 30 buprenorphine patients in their first year of prescribing the drug. They may apply to have this limit increased to 100 patients by year two and 275 patients by year three.
In December 2015, the US Government Accountability Office began a survey of the laws and regulations around opioid treatment programs and medication-assisted treatment and found that they were barriers to getting people with opioid use disorders the treatment they need. Despite the fact that there is a shortage of opioid treatment programs across the United States, many clinicians do not want to start their own because the time and effort required to comply with the regulations is prohibitive.
Individual-level barriers to accessing medication-assisted treatment also exist. The federal regulations regarding program admission into treatment programs are considered "high-threshold." Individuals seeking treatment must meet several criteria to be eligible for treatment. These criteria require potential patients to:
- Have a diagnosable opioid use disorder, according to the DSM-5,
- Be actively addicted to opioids at the time of intake, and
- Have been addicted to opioids for at least one year before beginning treatment.
In addition to these federal criteria, each state may have its own criteria individuals must meet. The US GAO also cited the cost of treatment and lack of health insurance coverage for MAT as barriers for many addicted to opioids. While methadone treatments are covered by Medicaid for low-income individuals, the extent of coverage depends on which state they are in and if the state has opted into Medicaid expansion under the Affordable Care Act.
Buprenorphine, on the other hand, is not covered by Medicaid or, often, even by private health insurers. Because buprenorphine must typically be paid for out-of-pocket, lower-income individuals are often priced out of the lower-risk MAT. In some areas this creates major disparities along racial lines with the higher-risk treatment utilized by lower-income individuals - disproportionately represented by people of color - and the lower-risk treatment only accessible to higher-income individuals - disproportionately represented by whites.
Other individual-level barriers may include transportation, especially for those who live in rural areas. The nearest Opioid Treatment Program (OTP) could be up to an hour away, and when daily methadone doses are required for treatment, this may interfere with the success of the MAT or the client's compliance in the program. In rural Vermont, 48% of respondents in treatment reported they had missed an appointment due to travel challenges. Because of issues like these, it is estimated that, nationwide, only 10% of individuals who would be eligible to receive MAT actually receive the treatment.
The price of opioid treatment may vary due to different factors, but the cost of treatment can range from $6,000 to $15,000 a year. Based on the research, most addicts come from lagging economic environment which multiple addicts do not have the support or funding to complete alternative medication for the addictions.
Methadone has been used for opioid dependence since 1964, and is the most-studied of the pharmacological treatment options. It is a synthetic long-acting opioid, so it can replace multiple heroin uses by being taken once daily. It works by binding to the opioid receptors in the brain and spinal cord, activating them, reducing withdrawal symptoms and cravings while suppressing the "high" that other opioids can elicit. The decrease in withdrawal symptoms and cravings allow the user to slowly taper off the drug in a controlled manner, decreasing the likelihood of relapse. It is not accessible to all addicts. It is a regulated substance, and requires that each dose be picked up from a methadone clinic daily. This can be inconvenient as some patients are unable to travel to a clinic, or wish to avoid the stigma associated with drug addiction.
Buprenorphine is used similarly to methadone, with some doctors recommending it as the best solution for medication-assisted treatment to help people reduce or quit their use of heroin or other opiates. It is claimed to be safer and less regulated than methadone, with month-long prescriptions allowed. It is also said to eliminate opiate withdrawal symptoms and cravings in many patients without inducing euphoria. Probuphine is an implantable form of buprenorphine lasting six months. Rates of buprenorphine use increased between 2003 and 2011, with sales increasing, on average, by 40%.
Unlike methadone treatment, which must be performed in a highly structured clinic, buprenorphine, according to SAMHSA, can be prescribed or dispensed in physician offices. Patients can thereby receive a full year of treatment for a fraction of the cost of detox programs.
Buprenorphine/naloxone is a combination medication that has been approved by the FDA in 2002 for treatment of opioid dependence. It is a combination medication that contains two separate drugs: buprenorphine and naloxone.
Buprenorphine works as a partial opioid agonist. It is given in combination with Naloxone because Naloxone works as an opioid antagonist, meaning it will block the effects of the opioid medication. This combination medication can reduce a person's opioid withdrawal symptoms while they are discontinuing opioids after a period of long-term use.
While buprenorphine/naloxone is indicated for the treatment of opioid use disorder, it does contain an opioid which means a person may be at risk of developing dependence to it as well.
Behavioral treatment is less effective without medical treatment during the initial detoxification. It has similarly been shown that medical treatments tend to get better results when accompanied by behavioral treatment. For opioid dependence, popular non-pharmacological treatment options include cognitive behavioral therapy (CBT), group or individual therapy, residential treatment centers, and twelve-step programs such as Narcotics Anonymous. Since addictive behavior is a learned behavior in opioid dependence, cognitive behavioral therapy aims to promote positive motivation to change that behavior. Studies such as the Rat Park series indicate that a greater focus on improving the environments of those with opioid use disorders could also be beneficial.
Harm reduction programs operate under the understanding that certain levels of drug use are inevitable and focus on minimizing adverse effects associated with drug use rather than stopping the behavior itself. In the context of the opioid epidemic, harm reduction strategies are designed to improve health outcomes and reduce overdose deaths. Because many pain sufferers are also depressed, a challenge of harm reduction is that some applications, such as the use of drugs to reverse or avoid opioid overdose can nullify the effects of antidepressant medications which depend on the natural human opioid system.
Naloxone (most commonly sold under the brand name Narcan) can be used as a rescue medication for opioid overdose or as a preventive measure for those wanting to stop using opiates. It is an opioid antagonist, meaning it binds to opioid receptors, which prevents them from being activated by opiates. It binds more strongly than other drugs, so that when someone is overdosing on opioids, naloxone can be administered, allowing it to take the place of the opioid drug in the person's receptors, turning them off. This blocks the effect of the receptors.
Many states have made Narcan available for purchase without a prescription. Additionally, police officers in many districts have begun carrying Narcan on a routine basis.
Take-home naloxone overdose prevention kits have shown promise in areas exhibiting rapid increases in opioid overdoses and deaths due to the increased availability of fentanyl and other synthetic opioids. Many counties offer Narcan training programs with the aim of educating the surrounding community on how to use Narcan. Early implementation of programs that widely distribute THN kits across these areas can substantially reduce the number of opioid overdose deaths. Additionally, persons at risk for opioid overdose did not engage in riskier, compensatory drug use as a result of having access to naloxone kits.
Overdose Prevention Centers
Despite the illegality of injecting illicit drugs in most places around the world, many injectable drug users report willingness to utilize Overdose Prevention Centers. Of these willing injectable drug users, those at especially high risk for opioid overdose were significantly more likely to be willing to use a safe injection site. This observed willingness suggests that safe injection sites would be well utilized by the very individuals who could benefit most from them.
As of 2018, legislation in the US did not allow for the opening of overdose prevention centers; there were no government-sponsored sites but several efforts were underway to try to create them.
Critics of Overdose Prevention Centers cite enabling drug users and even exacerbation of drug use as reasons for denying these programs. However, data as of 2014 suggested that safe injection sites could reduce overdoses while not increasing the number of drug users.
Needle exchange programs
The CDC defines needle exchange programs (NEP), also known as syringe services programs, as "community-based programs that provide access to sterile needles and syringes free of cost and facilitate safe disposal of used needles and syringes". NEP were first established in the US in the late 1980s as a response to the HIV pandemic. Because federal funding has long been banned from being used for NEP, their prominence in the US has been minimal. However, in early 2016, in the face of the ever-increasing heroin crisis, Congress effectively rolled back those regulations and is now allowing federal funding to support certain aspects of NEP. NEP are cited by the CDC as a vital aspect of the multi-faceted approach to the opioid crisis.
While opposition to NEP includes fears of increased drug use, studies have shown that they do not increase drug use among users or within a community. NEP have also been known to increase admittance into addiction treatment centers, offer counseling, housing support and help users begin the path to recovery through outreach from trusted staff. In addition, NEP that operate on a one-for-one basis help to drastically reduce the amount of discarded needles in public. Both the Center for Disease Control and National Institute of Health support the idea that NEP are a crucial aspect to a comprehensive approach to the opioid crisis.
Use of blue lights
As of 2018, some retailers had begun experimenting with the use of blue light bulbs in bathrooms in order to deter addicts from using such spaces to inject opiates. Blue lights are said to make finding veins to inject more difficult. However, a 2013 study has found that the use of blue lights are unlikely to deter drugs users from injecting in public washrooms and may increase drug use-related harm.
A "pill mill" is a clinic that dispenses narcotics to patients without a legitimate medical purpose. This is done at clinics and doctors offices, where doctors examine patients extremely quickly with a purpose of prescribing painkillers. These clinics often charge an office fee of $200 to $400 and can see up to 60 patients a day, which is very profitable for the clinic. Pill mills are also large suppliers of the illegal painkiller black markets on the streets. Dealers may hire people to go to pill mills to get painkiller prescriptions.
There have been attempts to shut down pill mills. 250 pill mills in Florida were shut down in 2015. Florida clinics also are no longer allowed to dispense painkillers directly from their clinics, which has helped reduce the distribution of prescription opiates. Since the implementation of pill mill laws and drug monitoring programs in Florida, high-risk patients (defined as those who use both benzodiazepines and opioids, those who have been using high opioid doses for extended periods of time, or "opioid shoppers" that obtain their opioid painkillers from multiple sources) have shown significant reductions in opioid use.
As the number of opioid prescriptions rose, drug cartels began flooding the US with heroin from Mexico. For many opioid users, heroin was cheaper, more potent, and often easier to acquire than prescription medications. According to the CDC, tighter prescription policies by doctors did not necessarily lead to this increased heroin use. The main suppliers of heroin to the US have been Mexican transnational criminal organizations.
From 2005 to 2009, Mexican heroin production increased by over 600%, from an estimated 8 metric tons in 2005 to 50 metric tons in 2009. Between 2010 and 2014, the amount seized at the border more than doubled. According to the Drug Enforcement Administration, smugglers and distributors "profit primarily by putting drugs on the street and have become crucial to the Mexican cartels.":3
Illicit fentanyl is commonly made in Mexico and trafficked by cartels. North America's dominant trafficking group is Mexico's Sinaloa Cartel, which has been linked to 80 percent of the fentanyl seized in New York.
- Diseases of despair – including opioid overdose
- Johnson & Johnson
- List of countries by prevalence of opiates use
- List of deaths from drug overdose and intoxication
- Opium in Iran, world's highest per capita rate of opiate addiction
- Teva Pharmaceutical Industries
- US drug overdose death rates and totals over time
- The Crime of the Century
- Opioid Data Analysis and Resources. Drug Overdose. CDC Injury Center. Centers for Disease Control and Prevention. Click on "Rising Rates" tab for a graph. See data table below the graph.
- Overdose Death Rates. By National Institute on Drug Abuse (NIDA).
- Guy GP, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. (July 2017). "Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015". MMWR. Morbidity and Mortality Weekly Report. 66 (26): 697–704. doi:10.15585/mmwr.mm6626a4. PMC 5726238. PMID 28683056.
- Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G (January 2018). "Drug and Opioid-Involved Overdose Deaths – United States, 2013–2017". MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1419–1427. doi:10.15585/mmwr.mm6751521e1. PMC 6334822. PMID 30605448.
- Hedegaard H (2018). "Drug overdose deaths in the United States, 1999-2017". NCHS Data Brief (329): 1–8. OCLC 1083547566. PMID 30500323.
- Affairs (ASPA), Assistant Secretary of Public (December 4, 2017). "What is the U.S. Opioid Epidemic?". HHS.gov. Retrieved December 16, 2019.
- Alhussain, Khalid, Shah, Drishti, Thornton, James, Kelly, Kimberly. Familial Opioid Misuse and Family Cohesion: Impact on Family Communication and Well-being. Addict Disorder Their Threat. 2019;18(4):194–204. doi:10.1097/ADT.0000000000000165.
- Underestimated cost of the opioid crisis [Whitehouse Web site]. November, 2017. Available at: [https://trumpwhitehouse.archives.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf www.whitehouse.gov]
- Results from the 2016 National Survey on Drug Use and Health. Detailed Tables. Substance Abuse and Mental Health Services Administration Web site; September 7, 2017. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf
- Why Do Adults Misuse Prescription Drugs? Rachel N. Lipari, Ph.D., Matthew Williams, Ph.D., and Struther L. Van Horn, M.A. Substance Abuse and Mental Health Services Administration Short Report July 27, 2017 
- Lebmke, A.; HUMPHREYS, K; NEWMARK, J (June 15, 2016). "Weighing the Risks and Benefits of Chronic Opioid Therapy". American Family Physicians Journal. 93 (12): 982–990. Retrieved June 13, 2021.
- Alexander GC, Kruszewski SP, Webster DW (November 2012). "Rethinking opioid prescribing to protect patient safety and public health". JAMA. 308 (18): 1865–6. doi:10.1001/jama.2012.14282. PMID 23150006.
- Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A (2011). "A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain". Pain Research & Management. 16 (5): 337–51. doi:10.1155/2011/465281. PMC 3206784. PMID 22059206.
- "U.S. Opioid Prescribing Rate Maps | Drug Overdose | CDC Injury Center". www.cdc.gov. March 12, 2020. Retrieved April 20, 2020.
- "Drug Facts: Prescription Opioids". NIDA. June 2019. Archived from the original on June 12, 2019. Retrieved July 5, 2019.
- "Why opioid overdose deaths seem to happen in spurts", CNN, February 8, 2017
- "Understanding the Epidemic | Drug Overdose | CDC Injury Center". www.cdc.gov. March 19, 2020. Retrieved April 20, 2020.
- Busse, Jason (April 30, 2018). "Opioids for Chronic Non-Cancer Pain: A Systematic Review of Randomized Controlled Trials". doi:10.26226/morressier.5ab3c87fa874c60026558b9a. Cite journal requires
- Turk, Dennis C.; Brody, Michael C.; Okifuji, Akiko E. (1994). "Physiciansʼ attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain". Pain. 59 (2): 201–208. doi:10.1016/0304-3959(94)90072-8. ISSN 0304-3959. PMID 7892017. S2CID 25488802.
- Organization, World Health (1986). Cancer pain relief (in Hindi). World Health Organization. hdl:10665/43944. ISBN 978-4-307-77043-9.
- "America's Addiction to Opioids: Heroin and Prescription Drug Abuse". archives.drugabuse.gov. May 14, 2014. Retrieved April 20, 2020.
- "Number of prescriptions dispensed by community pharmacies tops one billion for first time". The Pharmaceutical Journal. 2017. doi:10.1211/pj.2017.20203926. ISSN 2053-6186.
- Alexander GC, Kruszewski SP, Webster DW (November 2012). "Rethinking opioid prescribing to protect patient safety and public health". JAMA. 308 (18): 1865–6. doi:10.1001/jama.2012.14282. PMID 23150006.
- "America's opioid epidemic is worsening", The Economist (UK) March 6, 2017,
- "Results from the 2012 NSDUH: Summary of National Findings, SAMHSA, CBHSQ". www.samhsa.gov. Retrieved April 20, 2020.
- "Underlying Cause of Death 1999-2018". wonder.cdc.gov. Retrieved April 20, 2020.
- Mars, Sarah G.; Bourgois, Philippe; Karandinos, George; Montero, Fernando; Ciccarone, Daniel (2014). ""Every 'Never' I Ever Said Came True": Transitions from opioid pills to heroin injecting". International Journal of Drug Policy. 25 (2): 257–266. doi:10.1016/j.drugpo.2013.10.004. ISSN 0955-3959. PMC 3961517. PMID 24238956.
- Ruan, Xiulu, III; Wyche, Melville Q.; Kaye, Alan David (January 1, 2016). "Analyzing the relationship between nonmedical prescription-opioid use and heroin use". Journal of Opioid Management. 12 (1): 11–4. doi:10.5055/jom.2016.0315. ISSN 1551-7489. PMID 26943818.
- Gladden, R. Matthew; Martinez, Pedro; Seth, Puja (August 26, 2016). "Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid–Involved Overdose Deaths — 27 States, 2013–2014". MMWR. Morbidity and Mortality Weekly Report. 65 (33): 837–843. doi:10.15585/mmwr.mm6533a2. ISSN 0149-2195. PMID 27560775.
- Colon-Berezin, Cody; Nolan, Michelle L.; Blachman-Forshay, Jaclyn; Paone, Denise (January 18, 2019). "Overdose Deaths Involving Fentanyl and Fentanyl Analogs — New York City, 2000–2017". MMWR. Morbidity and Mortality Weekly Report. 68 (2): 37–40. doi:10.15585/mmwr.mm6802a3. ISSN 0149-2195. PMC 6336189. PMID 30653482.
- Shipton EA, Shipton EE, Shipton AJ (June 2018). "A Review of the Opioid Epidemic: What Do We Do About It?". Pain and Therapy. 7 (1): 23–36. doi:10.1007/s40122-018-0096-7. PMC 5993689. PMID 29623667.
- Amos O (October 25, 2017). "Why opioids are such an American problem". BBC News. Retrieved December 29, 2017.
- Erickson A (December 28, 2017). "Opioid abuse in the U.S. is so bad it's lowering life expectancy. Why hasn't the epidemic hit other countries?". The Washington Post. ISSN 0190-8286. Retrieved December 28, 2017.
- Daubresse M, Chang HY, Yu Y, Viswanathan S, Shah ND, Stafford RS, Kruszewski SP, Alexander GC (October 2013). "Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010". Medical Care. 51 (10): 870–8. doi:10.1097/MLR.0b013e3182a95d86. PMC 3845222. PMID 24025657.
- "The opioid epidemic could turn into a pandemic if we're not careful", The Washington Post, February 9, 2017
- "Opioid Prescriptions Fall After 2010 Peak, C.D.C. Report Finds", The New York Times, July 6, 2017
- "Missouri among five states selected to participate in project addressing maternal opioid use | opioids.mo.gov". opioids.mo.gov. Retrieved September 26, 2019.
- "Prescription Opioid Data". Centers for Disease Control and Prevention (CDC). Retrieved November 2, 2018.
- Abelson J, Williams A, Ba Tran A, Kornfield M (November 7, 2019). "At height of crisis, Walgreens handled nearly one in five of the most addictive opioids". Washington Post. Retrieved November 7, 2019.
- Opioid Crisis: What People Don't Know About Heroin, Rolling Stone
- Pergolizzi JV, LeQuang JA, Taylor R, Raffa RB (January 2018). "Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin". Postgraduate Medicine. 130 (1): 1–8. doi:10.1080/00325481.2018.1407618. PMID 29190175. S2CID 3492096.
- Fentanyl. Image 4 of 17. U.S. DEA (Drug Enforcement Administration).
- "Opioid epidemic shares chilling similarities with the past". Houston Chronicle. October 30, 2017. Archived from the original on November 7, 2017.
- Hicks RD (2011). "Frontline Pharmacies". Chemical Heritage Magazine. Retrieved October 29, 2018.
- Rinde M (2018). "Opioids' Devastating Return". Distillations. 4 (2): 12–23. Retrieved August 23, 2018.
- "The devastating effect of opioids on our society". August 26, 2016.
- Moghe S (May 12, 2016). "Opioids: From 'wonder drug' to abuse epidemic". CNN. Retrieved April 11, 2017.
- Caldwell, Christoper. "American Carnage: The New Landscape of Opioid Addiction", First Things, April 2017
- WGBH educational foundation. Interview with Dr. Robert DuPont. PBS.org (February 18, 1970)
- "Opioid crisis: The letter that started it all". BBC News. June 3, 2017. Retrieved June 3, 2017.
- Porter J, Jick H (January 1980). "Addiction rare in patients treated with narcotics". The New England Journal of Medicine. 302 (2): 123. doi:10.1056/NEJM198001103020221. PMID 7350425.
- Leung PT, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN (June 2017). "A 1980 Letter on the Risk of Opioid Addiction". The New England Journal of Medicine. 376 (22): 2194–2195. doi:10.1056/NEJMc1700150. PMID 28564561.
- Scott PD, Marshall J (1991). Cocaine Politics: Drugs, Armies, and the CIA in Central America. Berkeley, CA: University of California Press. p. 2.
- Van Zee A (February 2009). "The promotion and marketing of oxycontin: commercial triumph, public health tragedy". American Journal of Public Health. 99 (2): 221–7. doi:10.2105/AJPH.2007.131714. PMC 2622774. PMID 18799767.
- Keefe PR (October 2017). "The Family That Built an Empire of Pain: The Sackler dynasty's ruthless marketing of painkillers has generated billions of dollars—and millions of addicts". The New Yorker. A Reporter at Large. Retrieved October 26, 2017.
According to Forbes, the Sacklers are now one of America's richest families, with a collective net worth of thirteen billion dollars—more than the Rockefellers or the Mellons... While the Sacklers are interviewed regularly on the subject of their generosity, they almost never speak publicly about the family business, Purdue Pharma—a privately held company, based in Stamford, Connecticut, that developed the prescription painkiller OxyContin.Indepth-analysis
- "McKinsey Settles for Nearly $600 Million Over Role in Opioid Crisis". The New York Times. February 3, 2021. Archived from the original on February 18, 2021. Retrieved February 19, 2021.
- "Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives". National Institute on Drug Abuse. October 25, 2017. Retrieved November 10, 2017.
- Dowell D, Noonan RK, Houry D (December 2017). "Underlying Factors in Drug Overdose Deaths". JAMA. 318 (23): 2295–2296. doi:10.1001/jama.2017.15971. PMC 6007807. PMID 29049472.
- "2015 National Drug Threat Assessment Summary" (PDF). Drug Enforcement Administration. October 2015. Archived from the original (PDF) on February 20, 2017.
- Centers for Disease Control and Prevention (CDC) (November 4, 2011). "Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008". MMWR. Morbidity and Mortality Weekly Report. 60 (43): 1487–92. ISSN 0149-2195. PMID 22048730.
- "Drug overdoses now kill more Americans than guns". CBS News. December 9, 2016.
- Katz J (June 5, 2017). "Drug Deaths in America Are Rising Faster Than Ever". The Upshot. The New York Times.
- National Center for Health Statistics. "Provisional Counts of Drug Overdose Deaths, as of 8/6/2017" (PDF). Centers for Disease Control and Prevention (CDC). Source lists US totals for 2015 and 2016 and statistics by state.
- Lopez G (July 7, 2017). "In 2016, drug overdoses likely killed more Americans than the entire wars in Vietnam and Iraq". Vox. Vox Media.
- Nolan D, Amico C (February 23, 2016). "How Bad is the Opioid Epidemic?". Frontline. PBS.
- "America's Addiction to Opioids: Heroin and Prescription Drug Abuse" Archived June 14, 2017, at the Wayback Machine, National Institute on Drug Abuse (NIDA), May 14, 2014
- "STAT forecast: Opioids could kill nearly 500,000 Americans in the next decade", STAT, June 27, 2017,
- "Canada's opioid crisis is burdening the health care system, report warns". Globalnews.ca. September 14, 2017. Retrieved November 10, 2017.
- Miroff N (November 13, 2017). "Mexican traffickers making New York a hub for lucrative — and deadly — fentanyl". The Washington Post. Retrieved May 19, 2018.
- "White House: True cost of opioid epidemic tops $500 billion". November 20, 2017.
- "Overdose Crisis Mac Miller's Death". ABC News. Retrieved July 16, 2020.
- "'It's an overdose crisis': Mac Miller's death investigation highlights a dangerous trend in the opioid epidemic". ABC News. Retrieved July 16, 2020.
- "Opioid Overdose Crisis". National Institute on Drug Abuse. June 1, 2017. Retrieved November 10, 2017.
- Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, Alexander GC (March 2015). "The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction". Annual Review of Public Health. 36: 559–74. doi:10.1146/annurev-publhealth-031914-122957. PMID 25581144.
- Huang X, Keyes KM, Li G (January 2018). "Increasing Prescription Opioid and Heroin Overdose Mortality in the United States, 1999-2014: An Age-Period-Cohort Analysis". American Journal of Public Health. 108 (1): 131–136. doi:10.2105/AJPH.2017.304142. PMC 5719690. PMID 29161066.
- Frakt A (March 5, 2018). "Overshadowed by the Opioid Crisis: A Comeback by Cocaine". The New York Times.
- Anderson L (May 18, 2014). "Heroin: Effects, Addictions & Treatment Options". Drugs.com. Retrieved April 21, 2018.
- "What Science tells us About Opioid Abuse and Addiction". National Institute on Drug Abuse. January 27, 2016. Retrieved November 10, 2017.
- Now a counselor, she went from stoned to straight, San Francisco Chronicle, November 2. 2015.
- Meier B (May 10, 2007). "In Guilty Plea, OxyContin Maker to Pay $600 Million". The New York Times. Retrieved January 10, 2018.
- Coplan P (2012). Findings from Purdue's Post-Marketing Epidemiology Studies of Reformulated OxyContin's Effects (PDF). NASCSA 2012 Conference. Scottsdale, Arizona. Archived from the original (PDF) on June 14, 2013.
- Hwang CS, Chang HY, Alexander GC (February 2015). "Impact of abuse-deterrent OxyContin on prescription opioid utilization". Pharmacoepidemiology and Drug Safety. 24 (2): 197–204. doi:10.1002/pds.3723. PMID 25393216. S2CID 9335379.
- Office of the Commissioner. "Press Announcements – FDA requests removal of Opana ER for risks related to abuse". Fda.gov. Retrieved June 15, 2017.
- Cardia L, Calapai G, Quattrone D, Mondello C, Arcoraci V, Calapai F, Mannucci C, Mondello E (October 1, 2018). "Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review". Frontiers in Pharmacology. 9: 1122. doi:10.3389/fphar.2018.01122. PMC 6174210. PMID 30327606.
- "The Effects of Hydrocodone Use - DrugAbuse.com". drugabuse.com. July 17, 2012. Retrieved November 1, 2018.
- "A Quiet Drug Problem Among the Elderly". Retrieved November 1, 2018.
- "Hydrocodone Addiction and Abuse - Prescription Painkillers". AddictionCenter. Retrieved November 22, 2018.
- Library, CNN. "Opioid Crisis Fast Facts". CNN. Retrieved November 22, 2018.
- "Codeine Addiction and Abuse". AddictionCenter. Retrieved November 29, 2018.
- Agnich LE, Stogner JM, Miller BL, Marcum CD (September 2013). "Purple drank prevalence and characteristics of misusers of codeine cough syrup mixtures" (PDF). Addictive Behaviors. 38 (9): 2445–9. doi:10.1016/j.addbeh.2013.03.020. PMID 23688907.
- "Cough Syrup with Codeine Abuse, Also Known as Lean and Purple Drank". American Addiction Centers. Retrieved November 29, 2018.
- "Codeine Addiction: Signs, Overdose, & Withdrawal". American Addiction Centers. Retrieved November 29, 2018.
- "Fentanyl Takes a Deadly Toll on Vermont", VTDigger, June 4, 2017
- "Why fentanyl is deadlier than heroin, in a single photo", Stat, September 29, 2016
- "Fentanyl drug profile", The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
- "Fentanyl". Centers for Disease Control and Prevention (CDC). August 24, 2017. Retrieved November 10, 2017.
- "Online Sales of Illegal Opioids from China Surge in U.S.", The New York Times, January 24, 2018
- "Americans spent nearly $800M in 2 years on illegal fentanyl from China: 5 things to know", Becker's Hospital Review, January 25, 2018
- "Deadly synthetic opioids coming to US via 'dark web' and the postal service", Becker's Hospital Review, December 28, 2016
- "In China, Illegal Drugs Are Sold Online in an Unbridled Market", The New York Times, June 21, 2015
- "China 'stands ready to work with US' to crack down on opioid dealers using postal service to smuggle drugs", South China Morning Post, January 25, 2018
- "Deadly fentanyl bought online from China being shipped through the mail", "60 Minutes", CBS, April 28, 2019
- Katz J (September 2, 2017). "The First Count of Fentanyl Deaths in 2016: Up 540% in Three Years". The New York Times. ISSN 0362-4331. Retrieved December 29, 2017.
- "Orlando man pleads guilty to selling heroin mixed with fentanyl", Orlando.com, March 20, 2017
- "CDC Chief Frieden: How to end America's growing opioid epidemic", Fox News, December 17, 2016.
- "Opioid Data Analysis and Resources". Centers for Disease Control and Prevention (CDC). December 19, 2018. Retrieved July 23, 2019.
- "Prince's Autopsy Result Highlights Dangers of Opioid Painkiller Fentanyl", ABC News, June 2, 2016
- "Documents highlight Prince's struggle with opioid addiction", Seattle Times, April 17, 2017
- "Coroner: Franklin County fentanyl deaths hit 'unprecedented' rate of one per day", The Columbus Dispatch, March 16, 2017
- "'Truly terrifying': Chinese suppliers flood US and Canada with deadly fentanyl", STAT, April 5, 2016,
- "Addressing America's Fentanyl Crisis". National Institute of Drug Abuse. April 6, 2017.
- Park, Ju Nyeong; Rashidi, Emaan; Foti, Kathryn; Zoorob, Michael; Sherman, Susan; Alexander, G. Caleb (January 1, 2021). "Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011–2016". Drug and Alcohol Dependence. 218: 108416. doi:10.1016/j.drugalcdep.2020.108416. ISSN 0376-8716. PMC 7751390. PMID 33278761.
- Druga, Melina (May 5, 2020). "Study: Higher doses of naloxone potentially effective against synthetic opioids". Health Crisis Alert. Retrieved May 5, 2020.
- "Native American Overdose Deaths Surge Since Opioid Epidemic". Drug Discovery & Development. Associated Press. March 15, 2018. Retrieved March 15, 2018.
- Martins SS, Ghandour LA (February 2017). "Nonmedical use of prescription drugs in adolescents and young adults: not just a Western phenomenon". World Psychiatry. 16 (1): 102–104. doi:10.1002/wps.20350. PMC 5269500. PMID 28127929.
- "Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S." April 10, 2018. Retrieved June 27, 2019.
- Knight K (December 2017). "Women on the Edge: Opioids, Benzodiazepines, and the Social Anxieties Surrounding Women's Reproduction in the U.S. "Opioid Epidemic"". Contemporary Drug Problems. ProQuest 1970871903.
- Sullivan A (March 16, 2017). "The Opioid Epidemic Is This Generation's Pandemic Crisis". New York Magazine. Retrieved May 19, 2018.
- "Canada opioid crisis hits small cities hardest". BBC News. September 14, 2017. Retrieved May 19, 2018.
- "National report: apparent opioid-related deaths (2016)". Canada.ca. June 6, 2017. Retrieved November 10, 2017.
- "Prescription for Danger: A Report on the Troubling Trend of Prescription and Over-the-Counter Drug Abuse Among the Nation's Teens". US Office of National Drug Control Policy. Retrieved February 23, 2019.
- "Patient brokering exacerbates opioid crisis in Florida", South Bend Tribune, April 2, 2017
- de La Bruyere E (August 2, 2017). "Middletown, Ohio, a city under siege: 'Everyone I know is on heroin'". Yahoo.
- "Doctors must help remedy opioid crisis in Canada, CMA meeting hears". Cbc.ca. Retrieved November 10, 2017.
- Meyer K, Sholtis B (January 10, 2018). "Gov. Tom Wolf declares 'state of emergency' in Pa. opioid epidemic". WHYY. Retrieved May 19, 2018.
- Paulozzi LJ, Mack KA, Hockenberry JM, et al. (July 4, 2014). "Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012". MMWR. Morbidity and Mortality Weekly Report. 63 (26): 563–8. ISSN 0149-2195. PMC 4584903. PMID 24990489.
- "Heroin deaths surpass gun homicides for the first time, CDC data shows", The Washington Post, December 8, 2016, Retrieved May 8, 2017
- Whalen J (December 15, 2016). "The Children of the Opioid Crisis". The Wall Street Journal. Retrieved July 23, 2019.
- "How Addiction Affects the Family". Addiction Center. Retrieved April 30, 2020.
- Schonberg and Bourgois. Righteous Dopefiend.
- Schonberg and Bourgois. Righteous Dopefiend. pp. 117–146.
- Florence CS, Zhou C, Luo F, Xu L (October 2016). "The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013". Medical Care. 54 (10): 901–6. doi:10.1097/MLR.0000000000000625. PMC 5975355. PMID 27623005.
- "The true cost of opioid epidemic tops $500 billion, White House says". November 20, 2017.
- Phillips K (July 29, 2018). "A doctor was killed for refusing to prescribe opioids, authorities say". The Washington Post. Retrieved September 29, 2018.
- "U.S. House passes bill named for slain South Bend doctor to address opioid epidemic". South Bend Tribune. June 20, 2018. Retrieved September 29, 2018.
- "Injury Facts". injuryfacts.nsc.org. Retrieved January 14, 2019.
- Molina B (January 14, 2019). "Americans more likely to die of opioid overdose than car crash, says council report". www.poughkeepsiejournal.com. USA Today. Retrieved January 14, 2019.
- Lurie J. "A disturbing new phase of the opioid crisis: How rehab recruiters are luring recovering addicts into a deadly cycle". Mother Jones. Retrieved March 16, 2019.
- Ballreich, Jeromie; Mansour, Omar; Hu, Ellen; Chingcuanco, Francine; Pollack, Harold A.; Dowdy, David W.; Alexander, G. Caleb (November 4, 2020). "Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US". JAMA Network Open. 3 (11): e2023677. doi:10.1001/jamanetworkopen.2020.23677. ISSN 2574-3805. PMC 7643029. PMID 33146732.
- O'Donnell; Gladden, RA; Mattson, Cl (2020). "Vital signs: characteristics of drug overdose deaths involving opioids and stimulants: 24 states and the District of Columbia, January-June 2019". MMWR. Morbidity and Mortality Weekly Report. 69 (35): 1189–1197. doi:10.15585/mmwr.mm6935a1. PMC 7470457. PMID 32881854.
- "COVID-19 may be worsening opioid crisis, but states can take action". American Medical Association. May 28, 2020. Retrieved October 4, 2020.
- American Medical Association (August 14, 2020). "Issue brief: reports of increases in opioid-related overdose and other concerns during COVID pandemic" (PDF).
- Wainwright, JJ; Mikre, M (September 18, 2020). "Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak". JAMA. American Medical Association. 324 (16): 1674–1677. doi:10.1001/jama.2020.17694. PMC 7501585. PMID 32945855.
- Ochalak, TA; Cumpston, PL; Wils, BK (September 18, 2020). "Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic". JAMA. American Medical Association. 324 (16): 1673–1674. doi:10.1001/jama.2020.17477. PMC 7501586. PMID 32945832. S2CID 221787771.
- Haley, Danielle F.; Saitz, Richard (September 18, 2020). "The Opioid Epidemic During the COVID-19 Pandemic". JAMA. American Medical Association. 324 (16): 1615–1617. doi:10.1001/jama.2020.18543. PMID 32945831. S2CID 221788838.
- Abuse, National Institute on Drug (April 6, 2020). "COVID-19: Potential Implications for Individuals with Substance Use Disorders". www.drugabuse.gov. Retrieved April 15, 2020.
- "Once The Coronavirus Pandemic Subsides, The Opioid Epidemic Will Rage | Health Affairs". www.healthaffairs.org. doi:10.1377/hblog20200407.290720/full/ (inactive May 31, 2021). Retrieved April 15, 2020.CS1 maint: DOI inactive as of May 2021 (link)
- Nguyen, Thuy D.; Gupta, Sumedha; Ziedan, Engy; Simon, Kosali I.; Alexander, G. Caleb; Saloner, Brendan; Stein, Bradley D. (December 21, 2020). "Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic". JAMA Internal Medicine. 181 (4): 562–565. doi:10.1001/jamainternmed.2020.7497. ISSN 2168-6106. PMC 7754073. PMID 33346795.
- Timeline bar chart with 2016 number of deaths in the US from opioids. Originally at Overdose Death Rates. By National Institute on Drug Abuse (NIDA)
- Drug Overdose Deaths. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Click on a map year. The data table is below the map. Number of deaths for each state, and the age-adjusted rates of death for each state. Also, place cursor on map states to get data.
- "Poll: Many Utahns know people who seek treatment for opioid addiction, but barriers remain". The Salt Lake Tribune. April 3, 2017.
- "Secure and Responsible Drug Disposal Act of 2010" (PDF). Government Publishing Office. October 12, 2010.
- "Tackling the Opioid Public Health Crisis" (PDF). College of Physicians and Surgeons of Ontario. September 8, 2010. Archived from the original (PDF) on June 7, 2016.
- "First Do No Harm: Responding to Canada's Prescription Drug Crisis", Canadian Centre on Substance Abuse, March 2013
- "UK: Task Force offers ideas for opioid addiction solutions". Delhidailynews.com. June 11, 2014. Archived from the original on June 6, 2017. Retrieved January 7, 2016.
- Summary of the Comprehensive Addiction and Recovery Act, American Society of Addiction Medicine.
- "Facing Addiction in America" (PDF). US Surgeon General. 2016. p. 413. Archived from the original (PDF) on October 19, 2017.
- Higham S, Bernstein L (October 15, 2017). "How Congress allied with drug company lobbyists to derail the DEA's war on opioids". The Washington Post. Retrieved May 19, 2018.
- Mike DeBonis, Congress passes 21st Century Cures Act, boosting research and easing drug approvals, The Washington Post (December 7, 2016).
- Eilperin J, Johnson CY (December 13, 2016). "Obama paying tribute to Biden and bipartisanship, signs 21st Century Cures Act Tuesday". The Washington Post.
- "Opioid Epidemic: Trump to Set Up Commission on Addiction Crisis", NBC News, March 29, 2017
- "It's time to 'Trump' opioid addiction in the United States". The Hill. February 27, 2017.
- "President Trump Hosts an Opioid and Drug Abuse Listening Session". Real Clear Politics. March 29, 2017.
- "White House opioid commission to Trump: 'Declare a national emergency' on drug overdoses". The Washington Post. July 31, 2017.
- "Trump says opioid crisis is a national emergency, pledges more money and attention". The Washington Post. August 10, 2017.
- "Trump to tap Rep. Tom Marino as 'drug czar'". Politico. September 1, 2017. Retrieved October 13, 2017.
- Seelye KQ (October 10, 2015). "In Heroin Crisis, White Families Seek Gentler War on Drugs". The New York Times.
- Baker, Peter (October 17, 2017). "Tom Marino, Drug Czar Nominee, Withdraws in Latest Setback for Trump's Opioid Fight". The New York Times. Archived from the original on October 11, 2018. Retrieved September 7, 2020.
- Whitaker, Bill (October 17, 2017). "Ex-DEA agent: Opioid crisis fueled by drug industry and Congress". 60 Minutes. Archived from the original on August 31, 2020. Retrieved September 7, 2020.
- "FDA's Scott Gottlieb: Opioid addiction is FDA's biggest crisis now". CNBC. July 21, 2017. Archived from the original on August 29, 2020. Retrieved September 7, 2020.
- POLITICO Staff (February 9, 2018). "Trump to nominate Jim Carroll for 'drug czar". Politico.com. Arlington County, Virginia: Capitol News Company. Archived from the original on October 18, 2019.
- "APhA Attends Swearing-In Ceremony of National Drug Control Policy Director". Pharmacist.com. Washington, D.C.: American Pharmacists Association. February 4, 2019.
- McGreal C (March 21, 2019). "Opioid crisis: FDA's own staff demand agency halt approval of new painkillers". the Guardian. Retrieved March 22, 2019.
- "Major Science Report Lays Out a Plan to Tamp Down Opioid Crisis", Scientific American, July 13, 2017
- Turque B (March 1, 2017). "Maryland governor declares state of emergency for opioid crisis". The Washington Post.
- Seelye KQ (January 9, 2014). "In Annual Speech, Vermont Governor Shifts Focus to Drug Abuse Image". The New York Times.
- Hofmann M (January 12, 2018). "Lawmakers react to governor's opioid state of emergency". Herald Standard.
- Lopez G (October 31, 2017). "I looked for a state that's taken the opioid epidemic seriously. I found Vermont". Vox.
- "Trump declares opioids a public health emergency but pledges no new money". Chicago Tribune. October 26, 2017.
- "President Trump delivers speech on opioid crisis". PBS. October 26, 2017.
- "Integrating & Expanding Prescription Drug Monitoring Program Data" (PDF). Centers for Disease Control and Prevention (CDC). 2017.
- Wang LX (February 15, 2018). "The Complementarity of Health Information and Health IT for Reducing Opioid-Related Mortality and Morbidity". Rochester, NY. SSRN 3176809. Cite journal requires
- "#OpioidCrisis". #opioidcrisis. Retrieved November 7, 2018.
- "SUPPORT for Patients and Communities Act (H.R. 6)". GovTrack.us. Retrieved November 7, 2018.
- "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. Reuters. July 11, 2019. ISSN 0362-4331. Archived from the original on July 11, 2019. Retrieved September 7, 2020.
- Noor Zainab Hussain; Pushkala Aripaka; Nate Raymond (July 11, 2019). "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. Archived from the original on March 4, 2020. Retrieved September 7, 2020.
- "Trump Plans Crackdown on Fentanyl Shipments from China, Others", Bloomberg News, Sept. 10, 2019
- Jesse Eisinger; James Bandler (March 25, 2020). "Walmart Was Almost Charged Criminally Over Opioids. Trump Appointees Killed the Indictment". ProPublica.
- "Indivior Solutions Pleads Guilty to Felony Charge as Part of DOJ's Largest Opioid Resolution". uspsoig.gov. United States Postal Service Office of Inspector General. July 24, 2020. Retrieved September 7, 2020.
Indivior Solutions today pleaded guilty to a one-count felony information and, together with its parent companies Indivior Inc. and Indivior plc, agreed to pay a total of $600 million to resolve criminal and civil liability associated with the marketing of the opioid-addiction-treatment drug Suboxone. Together with a $1.4 billion resolution with Indivior’s former parent, Reckitt Benckiser Group PLC (RB Group), announced in 2019, and a plea agreement with Indivior plc’s former CEO, Shaun Thaxter, announced last month, the total resolution relating to the marketing of Suboxone is more than $2 billion — the largest-ever resolution in a case brought by the Department of Justice involving an opioid drug.
- Schoenberg S (July 13, 2016). "Led by Gov. Charlie Baker, 44 governors sign compact to address opioid addiction". MassLive.com. Advance Publications. Retrieved April 20, 2018.
- "A Compact to Fight Opioid Addiction", National Governors Assoc., July 13, 2016
- Pope, Adam (June 6, 2019). "State of addiction: How UAB is making an impact on the opioid crisis". UAB News. Birmingham AL: University of Alabama Birmingham.
- "Drilling into the DEA's pain pill data base". Washington Post. Washington DC: Nash Holdings Inc. January 17, 2020.
- Magtibay J (January 26, 2018). "Ducey signs sweeping law to confront Arizona opioid crisis". Retrieved January 29, 2018.
- "Number of overdose saves tops 500 through Arkansas program". Fox16News.com. Little Rock AR: NavStar Broadcasting. June 10, 2020.
- Davis K. "As opioid death toll worsens, California doctors will soon be required to check patient prescription drug history". Sandiego Union Tribune. Retrieved November 1, 2018.
- "One Senator's Push to Curb Opioid Abuse — and to Rein in the Facilities That Shelter Addicts - Voice of San Diego". Voice of San Diego. May 4, 2018. Retrieved November 2, 2018.
- "Bill Text - SB-1109 Controlled substances: Schedule II drugs: opioids". leginfo.legislature.ca.gov. Retrieved November 2, 2018.
- Houdesek, Carrie (February 21, 2020). "SF Project Is Arming The Public To Prevent Fatal Overdoses". KCBS-Radio. San Francisco CA: Entercon.
- Hernandez, Estiban (April 12, 2020). "Fatal drug overdoses involving fentanyl tripled in Denver between 2018 and 2019". Denverite. Denver CO: Spirited Media.
- Daily, John (May 28, 2019). "Colorado's Opioid Crisis Slows, In Part Because Of a Drug That Reverses Overdoses". CPR News. Centennial CO: Colorado Public Radio.
- Hearst Connecticut Editorial Board (August 27, 2020). "During the coronavirus, the opioid crisis in CT is only getting worse". Stamford Advocate. Stamford CT: Hearst Corp.
- "Delaware lawmakers tackle opioid addiction epidemic", Newsworks, March 23, 2017
- Blitz, Matt (August 31, 2020). "D.C. Is Doubling Availability Of Free Naloxone Due To Increase In Opioid-Related Deaths". DCist. Washington DC: WAMU American University. Archived from the original on September 3, 2020. Retrieved September 21, 2020.
- WSJ Online - 4 Senators Ask Florida to End Flamingo Express
- "Schumer Wants To End The Flamingo Express". Archived from the original on March 29, 2011. Retrieved February 21, 2011.
- "Schumer 1 Of 4 Senators Asking Florida To End Flamingo Express". February 20, 2011.
- Eldredge, Ellen (July 6, 2020). "Overdoses Are Surging, Check In On Your Friends And Family, Experts Say". GPB News. Atlanta GA: Georgia Public Broadcasting.
- Peer, Tracy (July 10, 2020). "Opioid overdoses: An epidemic within the pandemic". 11 Alive News. Atlanta GA: Tegna Corp.
- Finnerty, Ryan (August 20, 2020). "Hawaii Receives Federal Funding Amid National Spike In Drug Overdoses". Hawaii Public Radio. Honolulu HI.
- Sanchez, Melissa; Eldeib, Duaa (May 10, 2020). "Overdose Deaths Have Skyrocketed in Chicago, and the Coronavirus Pandemic May Be Making It Worse". ProPublica Illinois.org. Chicago IL: ProPublica.
- Chernoby, Kimberly; Nicolas, Terry (March 3, 2020). "Naloxone saves lives. Tainting it with criminality will mean people die". Washington Post. Washington DC: Nash Holdings.
- Morris, Tyrone (May 10, 2020). "Gov. Holcomb Says Indiana Will Provide $1M to Fund Narcan Distribution". 44News.com. Evansville IN: Allen Media Broadcasting.
- Blanchard, Sessi (April 15, 2020). "Narcan Inventor Condemns Indiana City Cops' Suspension of OD Reversals". Filter Magazine. New York NY: The Influence Foundation.
- Kansas to receive federal funds to fight opioid epidemic. (2017). (). Washington: Federal Information & News Dispatch, LLC. Retrieved from Criminal Justice Database
- Musgrave, Beth (August 31, 2020). "'Don't give up' After years of decline, Lexington's overdose deaths are rising fast". Kentucky.com. Lexington KY: McClatchy Co.
- Bunn, Terry (July 2020). "KYOD2A Happenings" (PDF). Kentucky Injury Prevention and Research Center. Lexington KY: Univ. of Kentucky.
- DEA. Greater New Orleans Situational Drug Report. 2017.https://www.dea.gov/sites/default/files/2018-10/2016%20Greater%20New%20Orleans%20Situational%20Drug%20Report%20FINAL.pdf
- "HOPE Council". Louisiana Department of Health.
- Louisiana Department of Health. The Louisiana Comprehensive Opioid Abuse Program (COAP) Action Plan. (2019) https://ldh.la.gov/assets/docs/BehavioralHealth/Grants/COAP_Strategic_Plan.pdf
- Louisiana Department of Health. Louisiana Comprehensive Opioid Abuse Program (LaCOAP). (2019).https://ldh.la.gov/assets/opioid/LaOpioidResponsePlan2019.pdf
- Abuse, National Institute on Drug (April 3, 2020). "Louisiana: Opioid-Involved Deaths and Related Harms". National Institute on Drug Abuse. Retrieved October 25, 2020.
- "Training - NOLA Ready". Retrieved October 25, 2020.
- "New Orleans Public Library Case Study" (PDF). ALA WebJunction. Retrieved October 25, 2020.
- Goeders, Nicholas (July 28, 2020). "The hidden health crisis resulting from COVID-19". Shreveport Times. Shreveport LA: Gannett.
- Derobertis, Jaqueline (May 3, 2020). "People who use drugs are more vulnerable to coronavirus. Here's what clinics are doing to help". The Advocate. Baton Rouge LA: Georges Media Group.
- "Hogan-Rutherford Administration Declares State of Emergency, Announces Major Funding to Combat Heroin and Opioid Crisis in Maryland", Maryland.gov, March 1, 2017
- "Gov. Hogan Announces Opioid Epidemic State of Emergency", CBS Baltimore, March 1, 2017
- Becker, Deborah (May 21, 2020). "The Pandemic Has Changed Addiction Treatment, Some Hope For Good". WBUR.org. Boston MA: Boston University.
- Burns, Julie (August 30, 2020). "Sounding the alarm: Seeing warning signs of an epidemic within the COVID pandemic". MASSLive.com. Springfield MA: Masslive Media.
- "Governor Snyder rolls out plan to fight opioid addiction", WILX, March 23, 2017
- "Snyder: Efforts to stop opioid abuse aren't working", Michigan Radio, March 23, 2017
- Revas, Rebecca (June 18, 2020). "Treating two pandemics: COVID and addiction". St. Louis American. St. Louis MO.
- Leonard, Krysten (September 6, 2020). "With opioid-related overdoses on the rise, health care providers try preparing everyday Nevadans to respond to a crisis". The Nevada Independent. Las Vegas NV: Nevada News Bureau Inc.
- Carter, Austin (September 5, 2020). "Study finds increase in drug overdose deaths amid pandemi". KTNV News. Las Vegas NV: Scripps Broadcasting Holdings.
- Grewal, Guber. "NJ Cares". Trenton NJ: Office of the Attorney General, State of New Jersey. Retrieved May 5, 2020.
- Jimenez, Stephanie (April 9, 2020). "Opioid Epidemic in New Jersey Takes Backseat to Coronavirus". NBC Philadelphia News. Philadelphia PA: NBC Telemundo.
- Shanes, Alexis; Janoski, Steve (April 24, 2020). "We already had an epidemic going on:' Recovering from substance abuse amid coronavirus crisis". NorthJersey.com. McLean VA: Gannett.
- Janoski, Steve (May 22, 2020). "New Jersey says doctors must prescribe Narcan alongside opioids for at-risk patients". NorthJersey.com. McLean VA: Gannett.
- Biryukov, Nikita (September 3, 2020). "New Jersey's EMS teams getting more than 11,000 doses of Narcan". New Jersey Globe. West Orange NJ: Sea of Reeds Media Inc.
- Hogan, Susie (September 6, 2019). "All Levels of Government Working Together to Combat the Opioid Crisis". NYSAC.org. Albany NY: New York State Association of Counties.
- Arpey, Jack (March 20, 2020). "What one Binghamton organization is doing to help recovering addicts as isolation takes its toll". WBNG-TV. Binghamton NY: Quincy Media Inc.
- Sharp, Brian (June 10, 2020). "Opioid overdoses spike 25% in Monroe County; bill would require pharmacies to offer Narcan". Rochester Democrat and Chronicle. Rochester NY: Gannett Inc.
- Penm J, MacKinnon NJ, Boone JM, Ciaccia A, McNamee C, Winstanley EL (2017). "Strategies and policies to address the opioid epidemic: A case study of Ohio". Journal of the American Pharmacists Association. 57 (2S): S148–S153. doi:10.1016/j.japh.2017.01.001. PMC 5497298. PMID 28189539.
- Caldwell, McKenzie (June 12, 2020). "Overdoses on the increase". timesgazette.com. Hillsboro OH: AIM Media Midwest.
- Feldman, Nina (May 29, 2020). "For Opioid Users, Pandemic Means New Dangers, But Also New Treatment Options". WHYY.org. Philadelphia PA: WHYY INC. NPR.
- Winberg, Micela (April 9, 2020). "Record-breaking Narcan shipments to prevent PA coronavirus overdose spike". Billy Penn. Philadelphia PA: WHYY Inc.
- Kurutz, Daveen Mae (September 5, 2020). "COVID sends opioid crisis into tailspin". Beaver County Times. Aliquippa PA: Gannett.
- Green, Daniel (March 25, 2020). "Coronavirus 'will drive up overdoses' as SC grapples with pandemic amid opioid crisis". Greenville News. Greenville Sc: Gannett.
- Raven, Jason (April 6, 2020). "Battling substance use disorder in South Carolina during the coronavirus pandemic". WIS TV News. Columbia SC: Gray Television.
- Levin, Dan (February 23, 2020). "Teaching children how to reverse an overdose". New York Times. New York NY.
- Kennedy, Corinne (June 5, 2020). "Overdoses are increasing during COVID-19 pandemic. A group of doctors is working 24/7 to change that". Memphis Commercial Appeal. Memphis TN: Gannett Inc.
- Lyapustina T, Rutkow L, Chang HY, Daubresse M, Ramji AF, Faul M, Stuart EA, Alexander GC (February 2016). "Effect of a "pill mill" law on opioid prescribing and utilization: The case of Texas". Drug and Alcohol Dependence. 159: 190–7. doi:10.1016/j.drugalcdep.2015.12.025. PMC 4976392. PMID 26778760.
- Loftus, Sawyer (June 21, 2020). "Overdoses rise at 'alarming' rate in Burlington and Vermont amid pandemic". VT Digger. Montpelier VT: Vermont Journalism Trust.
- Nygren, John. "Heroin, Opioid Prevention and Education". HOPE Agenda. HOPE Agenda. Retrieved November 2, 2018.
- "2017 Wisconsin Act 262". Wisconsin State Legislature. Wisconsin State Legislature. Retrieved November 2, 2018.
- "HB0299". le.utah.gov. Retrieved July 27, 2017.
- "U.S. City Sues OxyContin Maker for Contributing to Opioid Crisis". NPR. February 3, 2017. Retrieved October 26, 2017.
- Higham S, Bernstein L (March 9, 2017). "Opioid distributors sued by West Virginia counties hit by drug crisis". The Washington Post. Retrieved June 27, 2017.
- "Lawyer Behind West Virginia County Lawsuit Against Opioid Distributors". NPR.org. Retrieved June 27, 2017.
- "US trial opens against companies accused of stoking opioid crisis". Al Jazeera. May 3, 2021.
- "Founder and Four Executives of Insys Therapeutics Convicted of Racketeering Conspiracy". justice.gov. May 2, 2019. Retrieved May 14, 2019.
- "Insys Files For Chapter 11, Days After Landmark Opioid Settlement Of $225 Million". NPR. Retrieved May 10, 2020.
- Howard J, Drash W (August 26, 2019). "Oklahoma wins case against drugmaker in historic opioid triall". CNN. Retrieved August 26, 2019.
- Drash W (August 26, 2019). "From Ferris Bueller to opioid trial: A judge's wild ride into history". CNN. Retrieved August 26, 2019.
- Van Sant S (May 26, 2019). "Teva Pharmaceuticals Agrees To $85 Million Settlement With Oklahoma In Opioid Case". NPR. Retrieved August 26, 2019.
- Feeley, Jef (February 14, 2020). "States Reject Opioid Makers' $18 Billion Settlement Offer". Bloomberg.com. New York City: Bloomberg News.
- "Opioid crisis: US drug giants reach $26bn settlement". BBC News. July 21, 2021.
- Smith JC, Mulvihill G (October 21, 2019). "$260 million deal averts 1st federal trial on opioid crisis". Associated Press. New York NY.
- Randazzo, Sara (October 1, 2019). "Johnson & Johnson Agrees to Settle Ohio Opioid Lawsuits for $20.4 Million". Wall Street Journal. New York NY: Dow Jones and Company.
- Valena E. Beety *. "SYMPOSIUM: FROM THE CRIME SCENE TO THE COURTROOM: THE FUTURE OF FORENSIC SCIENCE REFORM: THE OVERDOSE/HOMICIDE EPIDEMIC." Georgia State University Law Review, 34, 983 Summer, 2018.
- Godvin M (November 26, 2019). "Perspective | My friend and I both took heroin. He overdosed. Why was I charged with his death?". Washington Post. Retrieved November 27, 2019.
- Northeastern University School of Law. "Health in Justice | Drug Induced Homicide | United States". Health In Justice Action Lab. Retrieved November 27, 2019.
- Drug Policy Alliance (November 2017). "An Overdose Death Is Not Murder: Why Drug-Induced Homicide Laws Are Counterproductive and Inhumane" (PDF). Drug Policy Alliance. p. 2. Retrieved November 27, 2019.
- Dowell D, Haegerich TM, Chou R (April 2016). "CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016". JAMA. 315 (15): 1624–45. doi:10.1001/jama.2016.1464. PMC 6390846. PMID 26977696.
- Missouri is final state to pass PDMP program; US News & World Report; April 13, 2017
- Alan M Jette, Responding to the Opioid Epidemic in the United States, Physical Therapy, Volume 98, Issue 3, March 2018, Pages 147–148
- Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC (March 2015). "Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access". Health Affairs. 34 (3): 484–92. doi:10.1377/hlthaff.2014.1085. PMID 25732500.
- Chang HY, Murimi I, Faul M, Rutkow L, Alexander GC (April 2018). "Impact of Florida's prescription drug monitoring program and pill mill law on high-risk patients: A comparative interrupted time series analysis". Pharmacoepidemiology and Drug Safety. 27 (4): 422–429. doi:10.1002/pds.4404. PMC 6664298. PMID 29488663.
- Perrone M. "Painkiller politics: Effort to curb prescribing under fire". The Washington Times. Associated Press. Retrieved June 13, 2017.
- Ghorayshi A. "Missouri Is the Only State in the US Where Doctors Have No Idea What Prescriptions People Are Getting". BuzzFeed. Retrieved April 11, 2017.
- Bennett D (May 22, 2018). "Report: Prescription drug monitoring programs not shown to affect drug overdoses". Santa Rosa's Press Gazette. Retrieved June 20, 2018.
- "Reversing the Opioid Epidemic". www.ama-assn.org. Retrieved November 7, 2018.
- "AMA Report Shows National Progress Toward Reversing Opioid Epidemic". www.ama-assn.org. Retrieved November 7, 2018.
- McGinty EE, Kennedy-Hendricks A, Baller J, Niederdeppe J, Gollust S, Barry CL (April 2016). "Criminal Activity or Treatable Health Condition? News Media Framing of Opioid Analgesic Abuse in the United States, 1998-2012". Psychiatric Services. 67 (4): 405–11. doi:10.1176/appi.ps.201500065. PMID 26620290.
- Netherland J, Hansen HB (December 2016). "The War on Drugs That Wasn't: Wasted Whiteness, "Dirty Doctors," and Race in Media Coverage of Prescription Opioid Misuse". Culture, Medicine and Psychiatry. 40 (4): 664–686. doi:10.1007/s11013-016-9496-5. PMC 5121004. PMID 27272904.
- The Washington Post. Casey, Libby, host. (October 17, 2017). "Talk to reporters and source behind our story on the drug industry's triumph over the DEA" Periscopetv website Retrieved November 3, 2017.
- Choo, Esther K.; Mazer-Amirshahi, Maryann; Juurlink, David; Kobner, Scott; Scott, Kevin; Lin, Michelle (January 2016). "The Prescription Opioid Epidemic: Social Media Responses to the Residents' Perspective Article". Annals of Emergency Medicine. 67 (1): 40–48. doi:10.1016/j.annemergmed.2015.05.005. ISSN 0196-0644. PMID 26169929.
- Hingham, Scott; Horwitz, Sara; Rich, Steven (June 16, 2019). "76 billion opioid pills: Newly released federal data unmasks the epidemic". Washington Post. Washington DC: Nash Holdings Inc.
- "Five takeaways from the DEA's pain pill database". Washington Post. Washington DC: Nash Holdings Inc. June 16, 2019.
- Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ (March 2010). "A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction". Clinical Psychology Review. 30 (2): 155–66. doi:10.1016/j.cpr.2009.10.006. PMID 19926374.
- Opioid Abuse~treatment at eMedicine
- McCarty D, Priest KC, Korthuis PT (April 2018). "Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities". Annual Review of Public Health. 39 (1): 525–541. doi:10.1146/annurev-publhealth-040617-013526. PMC 5880741. PMID 29272165.
- India.Young (June 15, 2015). "Certification of OTPs". www.samhsa.gov. Retrieved November 15, 2018.
- "Opioid Use Disorders: HHS Needs Measures to Assess the Effectiveness of Efforts to Expand Access to Medication-Assisted Treatment" (PDF). US Government Accountability Office. Retrieved November 15, 2018.
- "Opioid Addiction: Laws, Regulations, and Other Factors Can Affect Medication-Assisted Treatment Access" (PDF). US Government Accountability Office. Retrieved November 15, 2018.
- Vashishtha D, Mittal ML, Werb D (May 2017). "The North American opioid epidemic: current challenges and a call for treatment as prevention". Harm Reduction Journal. 14 (1): 7. doi:10.1186/s12954-017-0135-4. PMC 5427522. PMID 28494762.
- "eCFR — Code of Federal Regulations". www.ecfr.gov. Retrieved November 15, 2018.
- Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M (July 2013). "Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City". The Journal of Behavioral Health Services & Research. 40 (3): 367–77. doi:10.1007/s11414-013-9341-3. PMC 3818282. PMID 23702611.
- Johnson Q, Mund B, Joudrey PJ (June 2018). "Improving Rural Access to Opioid Treatment Programs". The Journal of Law, Medicine & Ethics. 46 (2): 437–439. doi:10.1177/1073110518782951. PMID 30146991. S2CID 52092013.
- "What are my treatment options?". TURN TO HELP. June 11, 2017. Archived from the original on June 30, 2017.[unreliable source?]
- "My View: New approach needed for opioid epidemic", Portland Tribune, July 25, 2017
- "New Medication Formulations Could Quickly Make a Difference for Treating Opioid Addiction". National Institute on Drug Abuse. August 22, 2017.
- Turner L, Kruszewski SP, Alexander GC (January 2015). "Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013". The American Journal on Addictions. 24 (1): 24–9. doi:10.1111/ajad.12174. PMID 25823632.
- Walsh L (June 15, 2015). "Buprenorphine". Samhsa.gov. Retrieved November 10, 2017.
- "The Effects of Suboxone Use". drugabuse.com. November 28, 2013. Retrieved November 1, 2018.
- Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. WHO Guidelines Approved by the Guidelines Review Committee. Geneva: World Health Organization. 2009. ISBN 9789241547543. PMID 23762965.
- Hall H (2019). "Opioids: The Good, the Bad, and the Ugly". Skeptical Inquirer. Vol. 43 no. 5. Center for Inquiry. pp. 19–21.
- Barglow P (July–August 2019). "Confessions of an American Opium-Prescriber". Skeptical Inquirer. Vol. 43 no. 4. Center for Inquiry. pp. 53–56. Retrieved March 6, 2020.
- Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, Kendall P, Kerr T, Gilbert M, Coombs D (May 2018). "Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study". The Lancet. Public Health. 3 (5): e218–e225. doi:10.1016/S2468-2667(18)30044-6. PMID 29678561.
- Jones JD, Campbell A, Metz VE, Comer SD (August 2017). "No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone". Addictive Behaviors. 71: 104–106. doi:10.1016/j.addbeh.2017.03.008. PMC 5449215. PMID 28325710.
- León C, Cardoso L, Mackin S, Bock B, Gaeta JM (January 2018). "The willingness of people who inject drugs in Boston to use a supervised injection facility". Substance Abuse. 39 (1): 95–101. doi:10.1080/08897077.2017.1365804. PMID 28799847.
- "Cities Planning Supervised Drug Injection Sites Fear Justice Department Reaction". NPR.org. Retrieved November 15, 2018.
- Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B (December 2014). "Supervised injection services: what has been demonstrated? A systematic literature review". Drug and Alcohol Dependence. 145: 48–68. doi:10.1016/j.drugalcdep.2014.10.012. PMID 25456324.
- "Determination of Need for Syringe Services Programs". Centers for Disease Control and Prevention (CDC). April 26, 2018. Retrieved May 2, 2018.
- Clarke K, Harris D, Zweifler JA, Lasher M, Mortimer RB, Hughes S (2016). "The Significance of Harm Reduction as a Social and Health Care Intervention for Injecting Drug Users: An Exploratory Study of a Needle Exchange Program in Fresno, California". Social Work in Public Health. 31 (5): 398–407. doi:10.1080/19371918.2015.1137522. PMC 5129746. PMID 27167664.
- Rudd RA, Seth P, David F, et al. (December 2016). "Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015". MMWR. Morbidity and Mortality Weekly Report. 65 (50–51): 1445–1452. doi:10.15585/mmwr.mm655051e1. PMID 28033313.
- Loue S, Lurie P, Lloyd LS (1995). "Ethical issues raised by needle exchange programs". The Journal of Law, Medicine & Ethics. 23 (4): 382–8. doi:10.1111/j.1748-720X.1995.tb01383.x. PMID 8715061. S2CID 6790182.
- "Understanding Drug Use and Addiction". National Institute on Drug Abuse. Retrieved May 2, 2018.
- Rubinkam M (June 24, 2018). "Retailers experiment with blue lights to deter drug use". ABC News. Archived from the original on June 24, 2018. Retrieved June 28, 2018.
- Crabtree A, Mercer G, Horan R, Grant S, Tan T, Buxton JA (October 2013). "A qualitative study of the perceived effects of blue lights in washrooms on people who use injection drugs". Harm Reduction Journal. 10: 22. doi:10.1186/1477-7517-10-22. PMC 3853159. PMID 24099145.
- "Signs of a Pill Mill in Your Community" (PDF). Kentucky Government. Kentucky Law Enforcement.
- "Dr. Procter's House -". October 3, 2016. Retrieved November 26, 2017.
- Quinones S (2015). Dreamland.
- "America's Pill Mills". DrugAbuse.com. July 1, 2016. Retrieved November 26, 2017.
- "Cracking Down on 'Pill Mill' Doctors". www.healthline.com. May 19, 2016. Retrieved November 26, 2017.
- "Heroin Production in Mexico and U.S. Policy", Congressional Research Service report, March 3, 2016
- Achenbach J (October 24, 2017). "Wave of addiction linked to fentanyl worsens as drugs, distribution, evolve". The Washington Post. Retrieved May 19, 2018.
- Alexander GC, Frattaroli S, Gielen AC, eds. (2017). The Opioid Epidemic: From Evidence to Impact (PDF). Baltimore, Maryland: Johns Hopkins Bloomberg School of Public Health.
- "CDC Guideline for Prescribing Opioids for Chronic Pain". US Centers for Disease Control and Prevention (CDC). April 17, 2019.
- Montgomery, Philip (October 30, 2017). "Faces of an Epidemic". The New Yorker.
- National Academies of Sciences, Engineering, and Medicine (2019). Leshner, Alan I; Mancher, Michelle (eds.). Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi:10.17226/25310. ISBN 978-0-309-48648-4. PMID 30896911.CS1 maint: multiple names: authors list (link)
- Emily Witt, "A Blizzard of Prescriptions" (review of Beth Macy, Dopesick, Head of Zeus, 2019; Chris McGreal, American Overdose: The Opioid Tragedy in Three Acts, Faber, 2018; Sam Quinones, Dreamland: The True Tale of America's Opiate Epidemic, Bloomsbury, 2016), London Review of Books, vol. 41, no. 7 (April 4, 2019), pp. 23–26. "OxyContin['s] lamentable [market] success was owed to a confluence of factors particular to the US. They include, but are not limited to: the country's dysfunctional privatised healthcare system, which makes it possible for addicts to accumulate doctors willing to prescribe painkillers in a way they can't in the UK; a corrupt regulatory agency [the Food and Drug Administration] beholden to the [pharmaceutical] industry it was tasked with regulating; a punitive legal paradigm that criminalises drug users instead of helping them; an abstinence-only approach to treating drug addiction that impedes evidence-based medication-assisted treatment; corporate greed; a political class that takes marching orders from the lobbyists of said corporations; entrenched poverty, joblessness and hopelessness; and a general epistemological failure when it comes to ideas about what 'drugs' are, which psychoactive chemicals are safe and which are dangerous, and what a drug dealer is supposed to look like. [This] prepared a consumer market for heroin. Hundreds of thousands of lives have been lost, each one of them a world." (Emily Witt, p. 23.)
- "The Opioid Files: Follow The Post's investigation of the opioid epidemic". The Washington Post. July 20, 2019. Retrieved July 23, 2019.